Immunoconjugates for DDR1 and methods of use

Abstract

Provided herein are anti-DDR1 antibodies and anti-DDR1 immunoconjugates. Such anti-DDR1 antibodies and anti-DDR1 immunoconjugates can be used for treating cancer.

Description

Attorney Docket No. 22419-20012.40IMMUNOCONJUGATES FOR DDR1 AND METHODS OF USECROSS REFERNCE TO RELATED APPLICATIONS

[0001] This application claims priority benefit U. S. Provisional Application Nos. 63 / 725,350, 63 / 789,313, 63 / 812,710, 63 / 878,026, 63 / 885,055, and 63 / 903,774, filed November 26, 2024, April 15, 2025, May 27, 2025, September 8, 2025, September 19, 2025, and October 22, 2025, respectively, the contents of each of which are hereby incorporated by reference in their entireties.REFERENCE TO AN ELECTRONIC SEQUENCE LISTING

[0002] The contents of the electronic sequence listing (224192001240SEQLIST.xml; Size: 509,358 bytes; and Date of Creation: November 14, 2025) is herein incorporated by reference in its entirety.FIELD OF INVENTION

[0003] The invention relates to anti-DDRl antibodies and anti-DDRl immunoconjugates, and methods of using the same for treating cancer.BACKGROUND

[0004] Discoidin domain receptor 1 (DDR1) is a receptor tyrosine kinase that recognizes collagen as its ligand. DDR1 regulates cell-collagen interactions in normal and pathological conditions and is an important sensor of collagen matrices. Specifically, in response to collagen binding, DDR1 mediates downstream signaling pathways including cell survival, cell growth, adhesion, extracellular matrix remodeling, and cell migration pathways. DDR1 is found to have abnormally elevated expression in various solid tumors, implying a critical role in cancer progression.

[0005] Current cancer treatments involve the use of cytotoxic drugs, chemotherapy, radiotherapy, and surgery, and often result in cancer recurrence. For example, cytotoxic drugs such as exatecan and its analogues are highly toxic and indiscriminate. Improved and targeted therapies are needed for targeting DDR1.BRIEF SUMMARY OF INVENTION

[0006] Provided herein are antibodies that bind DDR1 and immunoconjugates (e.g., antibody-drug conjugates (ADCs)) for DDR1 that address the previous limitations of cancer 1MF-363630230Attorney Docket No. 22419-20012.40treatments. For example, immunoconjugates for DDR1 described herein have lower affinity for normal tissue and as such represent an improved therapeutic.

[0007] Described herein, in certain embodiments, are antibodies or an antigen-binding fragments thereof that bind Discoidin Domain Receptor 1 (DDR1), comprising:a) a heavy chain variable region (VH) comprising at least about 90% sequence identity to any one of SEQ ID NOs: 153-155 and 171-173, at least about 91% sequence identity to any of SEQ ID NOs: 165-167, at least about 94% sequence identity to any one of SEQ ID NOs: 147-149 and 156-158, at least about 95% sequence identity to any one of SEQ ID NOs: 162-164, or at least about 97% sequence identity to any one of SEQ ID NOs: 150-152, 159-161, and 168-170; and b) a light chain variable region (VL) comprising at least about 95% sequence identity to any one of SEQ ID NOs: 195, 198, 201, 205, 206, 207, 209, 210, and 212, at least about 96% sequence identity to any one of SEQ ID NOs: 197, 200, and 203, at least about 97% sequence identity to any one of SEQ ID NOs: 187, 190, 193, 196, 199, and 202, at least about 98% sequence identity to any one of SEQ ID NOs: 188, 191, 194, 205, 208, and 211, or an amino acid sequence according to any one of SEQ ID NOs: 186, 189, and 192.

[0008] Described herein, in certain embodiments, are antibodies or an antigen-binding fragments thereof that bind Discoidin Domain Receptor 1 (DDR1), comprising:a) a heavy chain variable region (VH) comprising (i) a complementarity determining region (CDR) 1 having an amino acid sequence according to any one of SEQ ID NOs: 1-23; (ii) a CDR2 having an amino acid sequence according to any one of SEQ ID NOs: 24-46; and (iii) a CDR3 having an amino acid sequence according to any one of SEQ ID NOs: 47-69; andb) a light chain variable region (VL) comprising (i) a complementarity determining region (CDR) 1 having an amino acid sequence according to any one of SEQ ID NOs: 70-90; (ii) a CDR2 having an amino acid sequence according to any one of SEQ ID NOs: 91-111; and (iii) a CDR3 having an amino acid sequence according to any one of SEQ ID NOs: 112-132.

[0009] Described herein, in certain embodiments, are immunoconjugates comprising:a) an antibody or antigen-binding fragment that binds to Discoidin Domain Receptor 1 (DDR1), wherein the antibody or antigen-binding fragment thereof comprises:2MF-363630230Attorney Docket No. 22419-20012.40a heavy chain variable region (VH) comprising (i) a complementarity determining region (CDR) 1 having an amino acid sequence according to any one of SEQ ID NOs: 1-23; (ii) a CDR2 having an amino acid sequence according to any one of SEQ ID NOs: 24-46; and (iii) a CDR3 having an amino acid sequence according to any one of SEQ ID NOs: 47-69; anda light chain variable region (VL) comprising (i) a CDR1 having an amino acid sequence according to any one of SEQ ID NOs: 70-90; (ii) a CDR2 having an amino acid sequence according to any one of SEQ ID NOs: 91-111; and (iii) a CDR3 having an amino acid sequence according to any one of SEQ ID NOs: 112-132; and b) a topoisomerase I inhibitor conjugated to the antibody or the antigen-binding fragment thereof using a linker.

[0010] In some embodiments according to any of the embodiments described above, the topoisomerase I inhibitor is represented by Formula (II) having the structure:(II)wherein:R1and R2are each individually selected from the group consisting of hydrogen, halogen, -CN, -OR5, -NR5R6, a substituted or an unsubstituted Ci-Ce alkyl, a substituted or unsubstituted Ci-Ce haloalkyl, a substituted or unsubstituted -O-(Ci-Ce alkyl), a substituted or unsubstituted -O-(Ci-Ce haloalkyl), and - [(CY2)pO(CY2)q]tCY3, or a substituted or unsubstituted -O-(CR5R6)m-O- such that R1and R2are taken together form a ring;R3is a hydrogen or a substituted or an unsubstituted Ci-Ce alkyl, a substituted or an unsubstituted Ci-Ce haloalkyl, or — [(CY2)PO(CY2)q]tCY3;3MF-363630230Attorney Docket No. 22419-20012.40R4is hydrogen, a substituted or an unsubstituted — (Ci-Ce alkyl)-X2, a substituted or an unsubstituted — (Ci-Ce haloalkyl)-X2, a substituted or an unsubstituted — (Ci-Ce alkenyl)-X2, a substituted or an unsubstituted — (Ci-C6haloalkenyl)-X2, a substituted or an unsubstituted — (Ci-Ce alkynyl)-X2, or a substituted or an unsubstituted — (Ci- Ce haloalkynyl)-X2;X1is — O—, — S(O)W—, — NH—, — O— (C=O)—, — NH— (C=O)—, — NH— (C=O)— O—, — NH— (C=O)— NH—, or — NH— S(O)W—;X2is —OR9, —SR9, or — NHR9;R5and R6are each individually hydrogen, halogen, a substituted or an unsubstituted Ci-Ce alkyl, a substituted or an unsubstituted Ci-Ce haloalkyl, or — [(CY2)pO(CY2)q]tCY3;m is 1 or 2;n4and n5are each individually 0, 1 or 2, with the proviso that n4and n5are not both 0; each w is 0, 1 or 2;each Y is individually hydrogen or halogen;each p is individually 1, 2, 3, 4, 5, or 6;each q is individually 0, 1, 2, 3, 4, 5, or 6;each t is individually 1, 2, 3, 4, 5, or 6;R7is hydrogen, — COR8, — CO2R8, — (CO) — NHR8, or the point of attachment to the linker;R8is a substituted or an unsubstituted Ci-Ce alkyl-X3, a substituted or an unsubstituted Ci-Ce haloalkyl-X3, or — [(CY2)PO(CY2)q]tCY2 — X3;R9is hydrogen, — COR8, — CO2R8, — (CO) — NHR8, or the point of attachment to the linker, with the proviso that exactly one of R7and R9is the point of attachment to the linker; andeach X3is individually — H, — OH, — SH, or — NH2.

[0011] In some embodiments according to any of the embodiments described above, the topoisomerase I inhibitor is represented by Formula (II) having the structure:4MF-363630230Attorney Docket No. 22419-20012.40(II)wherein:R1and R2are each individually selected from the group consisting of hydrogen, halogen, -OR5, unsubstituted Ci-Ce alkyl, unsubstituted Ci-Ce haloalkyl and unsubstituted -O-(Ci-Ce alkyl), or unsubstituted -O-(CR5R6)m-O- such that R1and R2are taken together form a ring;R3is hydrogen or unsubstituted Ci-Ce alkyl;R4is a substituted or an unsubstituted — (Ci-Ce alkyl)-X2;X1is — O—;X2is —OR9;R5and R6are each individually hydrogen;m is 1;n4is 1 or 2;n5is 0;R7is hydrogen; andR9is the point of attachment to the linker.

[0012] In some embodiments according to any of the embodiments described above, n4is 1.

[0013] In some embodiments according to any of the embodiments described above, n4is 2.

[0014] In some embodiments according to any of the embodiments described above, topoisomerase I inhibitor comprises Formula (II) having the structure:5MF-363630230Attorney Docket No. 22419-20012.40wherein:R1is methyl;R2is fluoro;R3is hydrogen;R4is a substituted or an unsubstituted -(C2 alkyl)-X2; andn4is 2,and wherein the remaining variables are as described herein.

[0015] In some embodiments according to any of the embodiments described above, the topoisomerase I inhibitor is represented by:OR9wherein R9is the point of attachment to the linker.

[0016] In some embodiments according to any of the embodiments described above, the topoisomerase I inhibitor is represented by:6MF-363630230Attorney Docket No. 22419-20012.40wherein R9is the point of attachment to the linker.

[0017] In some embodiments according to any of the embodiments described above, the topoisomerase I inhibitor is represented by:wherein R9is the point of attachment to the linker.

[0018] In some embodiments according to any of the embodiments described above, the topoisomerase I inhibitor and the linker, taken together, are represented by:7MF-363630230Attorney Docket No. 22419-20012.40

[0019] In some embodiments according to any of the embodiments described above, the topoisomerase I inhibitor and the linker, taken together, are represented by:

[0020] In some embodiments according to any of the embodiments described above, the topoisomerase I inhibitor and the linker, taken together, are represented by:8MF-363630230Attorney Docket No. 22419-20012.40

[0021] In some embodiments according to any of the embodiments described above, the topoisomerase I inhibitor and the linker, taken together, are represented by:

[0022] In some embodiments according to any of the embodiments described above, the topoisomerase I inhibitor and the linker, taken together, are represented by:9MF-363630230Attorney Docket No. 22419-20012.40

[0023] Described herein, in certain embodiments, are immunoconjugates having Formula (I),Ab-[S-L1-L2-L3-L4-L5-L6-L7-D]n(I)wherein:Ab is an antibody or an antigen-binding fragment thereof that binds Discoidin Domain Receptor 1 (DDR1), comprising:a heavy chain variable region (VH) comprising (i) a complementarity determining region (CDR) 1 having an amino acid sequence according to any one of SEQ ID NOs: 1-23; (ii) a CDR2 having an amino acid sequence according to any one of SEQ ID NOs: 24-46; and (iii) a CDR3 having an amino acid sequence according to any one of SEQ ID NOs: 47-69; anda light chain variable region (VL) comprising (i) a CDR1 having an amino acid sequence according to any one of SEQ ID NOs: 70-90; (ii) a CDR2 having an amino acid sequence according to any one of SEQ ID NOs: 91-111; and (iii) a CDR3 having an amino acid sequence according to any one of SEQ ID NOs: 112-132;S is a sulfur atom of a cysteine of the antibody or the antigen-binding fragment thereof;L1isL2is absent,10MF-363630230Attorney Docket No. 22419-20012.40Z1z1Z1and Z2are each individually hydrogen, halogen, NO2, -O-(Ci-Ce alkyl), or Ci-Ce alkyl;L3is -(CH2)n1-C(=O)- or -(CH2CH2O)n1-(CH2)n1C(=O)-;each n1is individually an integer from 0 to 10;L4is a tetrapeptide residue;L5is absent or -[NH(CH2)n2]n3- n2is an integer from 0 to 6;n3is an integer from 0 to 2;L6is absent,, wherein G is a beta- glucuronic acidL7is absent,D is a drug moiety; andn is an integer from 1 to 10.

[0024] In some embodiments according to any of the embodiments described above, the drug moiety is represented by Formula (II) having the structure:11MF-363630230Attorney Docket No. 22419-20012.40(II)wherein:R1and R2are each individually selected from the group consisting of hydrogen, halogen, -CN, -OR5, -NR5R6, a substituted or an unsubstituted Ci-Ce alkyl, a substituted or unsubstituted Ci-Ce haloalkyl, a substituted or unsubstituted -O-(Ci-Ce alkyl), a substituted or unsubstituted -O-(Ci-Ce haloalkyl), and -[(CY2)pO(CY2)q]tCY3, or a substituted or unsubstituted -O-(CR5R6)m-O- such that R1and R2are taken together form a ring;R3is a hydrogen, a substituted or an unsubstituted Ci-Ce alkyl, a substituted or an unsubstituted Ci-Ce haloalkyl, or — [(CY2)PO(CY2)q]tCY3;R4is hydrogen, a substituted or an unsubstituted — (Ci-Ce alkyl)-X2, a substituted or an unsubstituted — (Ci-Ce haloalkyl)-X2, a substituted or an unsubstituted — (Ci-Ce alkenyl)-X2, a substituted or an unsubstituted — (Ci-C6haloalkenyl)-X2, a substituted or an unsubstituted — (Ci-Ce alkynyl)-X2, or a substituted or an unsubstituted — (Ci-Ce haloalkynyl)-X2;X1is — O—, — S(O)W—, — NH—, — O— (C=O)—, — NH— (C=O)—, — NH— (C=O)— O—, — NH— (C=O)— NH—, or — NH— S(O)W—;X2is —OR9, —SR9, or — NHR9;R5and R6are each individually hydrogen, halogen, a substituted or an unsubstituted Ci-Ce alkyl, a substituted or an unsubstituted Ci-Ce haloalkyl, or — [(CY2)pO(CY2)q]tCY3;m is 1 or 2;12MF-363630230Attorney Docket No. 22419-20012.40n4and n5are each individually 0, 1 or 2, with the proviso that n4and n5are not both 0; each w is 0, 1 or 2;each Y is individually hydrogen or halogen;each p is individually 1, 2, 3, 4, 5, or 6;each q is individually 0, 1, 2, 3, 4, 5, or 6;each t is individually 1, 2, 3, 4, 5, or 6;R7is H, —COR8, — CO2R8, — (CO)— NHR8, L4, L5, L6, or L7;R8is a substituted or an unsubstituted Ci-Ce alkyl-X3, a substituted or an unsubstituted Ci-Ce haloalkyl-X3, or — [(CY2)pO(CY2)q]tCY2 — X3;R9is hydrogen, — COR8, — CO2R8, — (CO) — NHR8, L4, L5, L6, or L7, with the proviso that exactly one of R7and R9is L4, L5, L6, or L7; andeach X3is individually — H, — OH, — SH, or — NH2.

[0025] In some embodiments according to any of the embodiments described above, the drug moiety of Formula (II) is represented by:(II)wherein:R1and R2are each individually selected from the group consisting of hydrogen, halogen, -OR5, unsubstituted Ci-Ce alkyl, unsubstituted Ci-Ce haloalkyl, and unsubstituted -O-(Ci-Ce alkyl), or unsubstituted -O-(CR5R6)m-O- such that R1and R2are taken together form a ring;R3is a hydrogen or an unsubstituted Ci-Ce alkyl;13MF-363630230Attorney Docket No. 22419-20012.40R4is a substituted or an unsubstituted — (Ci-Ce alkyl)-X2;X1is — O—;X2is —OR9;R5and R6are each individually hydrogen;m is 1;n4is 1 or 2;n5is 0;R7is hydrogen; andR9is L4, L5, L6, or L7.

[0026] In some embodiments according to any of the embodiments described above, n4is 1.

[0027] In some embodiments according to any of the embodiments described above, n4is 2.

[0028] In some embodiments according to any of the embodiments described above, the drug moiety of Formula (II) is represented by:R1is methyl;R2is fluoro;R3is hydrogen;R4is a substituted or an unsubstituted -(C2 alkyl)-X2; andn4is 2,and wherein the remaining variables are as described herein.

[0029] In some embodiments according to any of the embodiments described above, L2is absent;n1is the integer 2 or 5;L4is gly-gly-phe-gly;14MF-363630230Attorney Docket No. 22419-20012.40L5is -[NH(CH2)n2]n3-;n2is the integer 1;n3is the integer 1; andL7is absent,and wherein the remaining variables are as described herein.

[0030] In some embodiments according to any of the embodiments described above, the drug moiety of Formula (II) is represented by:

[0031] In some embodiments according to any of the embodiments described above, the drug moiety of Formula (II) is represented by:

[0032] In some embodiments according to any of the embodiments described above, the drug moiety of Formula (II) is represented by:15MF-363630230Attorney Docket No. 22419-20012.40OH Owherein R9is L4, L5, L6, or L7.

[0033] In some embodiments according to any of the embodiments described above, Formula (I) is represented by:wherein n is as described herein.

[0034] In some embodiments according to any of the embodiments described above, Formula (I) is represented by:16MF-363630230Attorney Docket No. 22419-20012.40wherein n is as described herein.

[0035] In some embodiments according to any of the embodiments described above, Formula (I) is represented by:17MF-363630230Attorney Docket No. 22419-20012.40wherein n is as described herein.

[0036] In some embodiments according to any of the embodiments described above, Formula (I) is represented by:wherein n is as described herein.

[0037] In some embodiments according to any of the embodiments described above, Formula (I) is represented by:18MF-363630230Attorney Docket No. 22419-20012.40wherein n is as described herein.

[0038] Described herein, in certain embodiments, are immunoconjugates having Formula (I),Ab-[S-L1-L2-L3-L4-L5-L6-L7-D]n(I)wherein:Ab is an antibody or an antigen-binding fragment thereof that binds Discoidin Domain Receptor 1 (DDR1), comprising:a heavy chain variable region (VH) comprising (i) a complementarity determining region (CDR) 1 having an amino acid sequence according to any one of SEQ ID NOs: 1-23; (ii) a CDR2 having an amino acid sequence according to any one of SEQ ID NOs: 24-46; and (iii) a CDR3 having an amino acid sequence according to any one of SEQ ID NOs: 47-69; anda light chain variable region (VL) comprising (i) a CDR1 having an amino acid sequence according to any one of SEQ ID NOs: 70-90; (ii) a CDR2 having an amino acid sequence according to any one of SEQ ID NOs: 91-111; and (iii) a CDR3 having an amino acid sequence according to any one of SEQ ID NOs: 112-132;19MF-363630230Attorney Docket No. 22419-20012.40S is a sulfur atom of a cysteine of the antibody or the antigen-binding fragment thereof;L2is absent,Z1and Z2are each individually hydrogen, halogen, NO2, -O-(Ci-Ce alkyl), or Ci-Ce alkyl;L3is -(CH2)n1-C(=O)- or -(CH2CH2O)n1-(CH2)n1C(=O)-;each n1is individually an integer from 0 to 10;L4is a tetrapeptide residue;L5is absent or -[NH(CH2)n2]n3- n2is an integer from 0 to 6;n3is an integer from 0 to 2;L6is absent,H N O, or, wherein G is a beta- glucuronic acid moiety;L7is absent,20MF-363630230Attorney Docket No. 22419-20012.40wherein D has the structure:OH Oandn is an integer from 1 to 10.

[0039] In some embodiments according to any of the embodiments described above, n is an integer from 4 to 8.

[0040] In some embodiments according to any of the embodiments described above, the VH comprises an amino acid sequence having at least about 80% sequence identity to any one of SEQ ID NOs: 133-173.

[0041] In some embodiments according to any of the embodiments described above, the VL comprises an amino acid sequence having at least about 80% sequence identity to any one of SEQ ID NOs: 174-212.

[0042] In some embodiments according to any of the embodiments described above, the VH comprises an amino acid sequence having at least about 80% sequence identity to any one of SEQ ID NOs: 133-173 and the VL comprises an amino acid sequence having at least about 80% sequence identity to any one of SEQ ID NOs: 174-212.

[0043] In some embodiments according to any of the embodiments described above, the VH comprises an amino acid sequence according to any one of SEQ ID NOs: 133-173.

[0044] In some embodiments according to any of the embodiments described above, the VL comprises an amino acid sequence according to any one of SEQ ID NOs: 174-212.

[0045] In some embodiments according to any of the embodiments described above, the VH comprises an amino acid sequence according to any one of SEQ ID NOs: 133-173 and the VL comprises an amino acid sequence according to any one of SEQ ID NOs: 174-212.

[0046] In some embodiments according to any of the embodiments described above, the antibody or the antigen-binding fragment comprises:21MF-363630230Attorney Docket No. 22419-20012.40i) a VH comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 1, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 24, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 47; and a VL comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 70, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 91, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 112;ii) a VH comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 2, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 25, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 48; and a VL comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 71, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 92, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 113;iii) a VH comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 3, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 26, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 49; and a VL comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 72, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 93, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 114;iv) a VH comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 4, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 27, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 50; and a VL comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 73, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 94, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 115;v) a VH comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 5, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 28, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 51; and a VL comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 74, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 95, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 116;vi) a VH comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 6, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 29, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 52; and a VL comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 75,22MF-363630230Attorney Docket No. 22419-20012.40(ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 96, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 117;vii) a VH comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 7, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 30, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 53; and a VL comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 76, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 97, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 118;viii) a VH comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 8, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 31, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 54; and a VL comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 77, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 98, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 119;ix) a VH comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 9, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 32, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 55; and a VL comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 78, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 99, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 120;x) a VH comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 10, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 33, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 56; and a VL comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 79, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 100, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 121; xi) a VH comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 11, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 34, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 57; and a VL comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 80, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 101, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 122; xii) a VH comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 12, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 35,23MF-363630230Attorney Docket No. 22419-20012.40and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 58; and a VL comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 81, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 102, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 123; xiii) a VH comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 13, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 36, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 59; xiv) a VH comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 14, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 37, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 60; xv) a VH comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 15, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 38, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 61; and a VL comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 82, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 103, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 124; xvi) a VH comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 16, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 39, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 62; and a VL comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 83, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 104, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 125; xvii) a VH comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 17, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 40, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 63; and a VL comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 84, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 105, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 126; xviii) a VH comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 18, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 41, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 64; and a VL comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 85, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 106, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 127;24MF-363630230Attorney Docket No. 22419-20012.40xix) a VH comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 19, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 42, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 65; and a VL comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 86, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 107, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 128; xx) a VH comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 20, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 43, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 66; and a VL comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 87, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 108, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 129; xxi) a VH comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 21, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 44, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 67; and a VL comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 88, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 109, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 130; xxii) a VH comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 22, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 45, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 68; and a VL comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 89, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 110, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 131; or xxiii) a VH comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 23, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 46, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 69; and a VL comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 90, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 111, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 132.

[0047] In some embodiments according to any of the embodiments described above, the antibody or the antigen-binding fragment comprises:25MF-363630230Attorney Docket No. 22419-20012.40a) a VH comprising an amino acid sequence according to SEQ ID NO: 133, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 133, and a VL comprising an amino acid sequence according to SEQ ID NO: 174, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 174;b) a VH comprising an amino acid sequence according to SEQ ID NO: 134, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 134, and a VL comprising an amino acid sequence according to SEQ ID NO: 175, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 175;c) a VH comprising an amino acid sequence according to SEQ ID NO: 135, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 135, and a VL comprising an amino acid sequence according to SEQ ID NO: 176, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 176;d) a VH comprising an amino acid sequence according to SEQ ID NO: 136, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 136, and a VL comprising an amino acid sequence according to SEQ ID NO: 177, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 177;e) a VH comprising an amino acid sequence according to SEQ ID NO: 137, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 137, and a VL comprising an amino acid sequence according to SEQ ID NO: 178, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 178;f) a VH comprising an amino acid sequence according to SEQ ID NO: 138, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 138, and a VL comprising an amino acid sequence according to SEQ ID NO: 179, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 179;g) a VH comprising an amino acid sequence according to SEQ ID NO: 139, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 139, and a VL comprising an amino acid sequence according to SEQ ID NO: 180, or an26MF-363630230Attorney Docket No. 22419-20012.40amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 180;h) a VH comprising an amino acid sequence according to SEQ ID NO: 140, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 140, and a VL comprising an amino acid sequence according to SEQ ID NO: 181, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 181;i) a VH comprising an amino acid sequence according to SEQ ID NO: 141, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 141; j) a VH comprising an amino acid sequence according to SEQ ID NO: 142, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 142, and a VL comprising an amino acid sequence according to SEQ ID NO: 182, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 182;k) a VH comprising an amino acid sequence according to SEQ ID NO: 143, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 143, and a VL comprising an amino acid sequence according to SEQ ID NO: 183, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 183;l) a VH comprising an amino acid sequence according to SEQ ID NO: 144, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 144, and a VL comprising an amino acid sequence according to SEQ ID NO: 184, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 184;m) a VH comprising an amino acid sequence according to SEQ ID NO: 145, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 145; n) a VH comprising an amino acid sequence according to SEQ ID NO: 146, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 146, and a VL comprising an amino acid sequence according to SEQ ID NO: 185, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 185;o) a VH comprising an amino acid sequence according to SEQ ID NO: 147, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 147, and a VL comprising an amino acid sequence according to SEQ ID NO: 186, or an 27MF-363630230Attorney Docket No. 22419-20012.40amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 186;p) a VH comprising an amino acid sequence according to SEQ ID NO: 148, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 148, and a VL comprising an amino acid sequence according to SEQ ID NO: 187, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 187;q) a VH comprising an amino acid sequence according to SEQ ID NO: 149, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 149, and a VL comprising an amino acid sequence according to SEQ ID NO: 188, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 188;r) a VH comprising an amino acid sequence according to SEQ ID NO: 150, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 150, and a VL comprising an amino acid sequence according to SEQ ID NO: 189, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 189;s) a VH comprising an amino acid sequence according to SEQ ID NO: 151, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 151, and a VL comprising an amino acid sequence according to SEQ ID NO: 190, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 190;t) a VH comprising an amino acid sequence according to SEQ ID NO: 152, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 152, and a VL comprising an amino acid sequence according to SEQ ID NO: 191, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 191;u) a VH comprising an amino acid sequence according to SEQ ID NO: 153, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 153, and a VL comprising an amino acid sequence according to SEQ ID NO: 192, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 192;v) a VH comprising an amino acid sequence according to SEQ ID NO: 154, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 154,28MF-363630230Attorney Docket No. 22419-20012.40and a VL comprising an amino acid sequence according to SEQ ID NO: 193, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 193;w) a VH comprising an amino acid sequence according to SEQ ID NO: 155, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 155, and a VL comprising an amino acid sequence according to SEQ ID NO: 194, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 194;x) a VH comprising an amino acid sequence according to SEQ ID NO: 156, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 156, and a VL comprising an amino acid sequence according to SEQ ID NO: 195, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 195;y) a VH comprising an amino acid sequence according to SEQ ID NO: 157, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 157, and a VL comprising an amino acid sequence according to SEQ ID NO: 196, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 196;z) a VH comprising an amino acid sequence according to SEQ ID NO: 158, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 158, and a VL comprising an amino acid sequence according to SEQ ID NO: 197, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 197;aa) a VH comprising an amino acid sequence according to SEQ ID NO: 159, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 159, and a VL comprising an amino acid sequence according to SEQ ID NO: 198, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 198;bb) a VH comprising an amino acid sequence according to SEQ ID NO: 160, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 160, and a VL comprising an amino acid sequence according to SEQ ID NO: 199, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 199;29MF-363630230Attorney Docket No. 22419-20012.40cc) a VH comprising an amino acid sequence according to SEQ ID NO: 161, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 161, and a VL comprising an amino acid sequence according to SEQ ID NO: 200, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 200;dd) a VH comprising an amino acid sequence according to SEQ ID NO: 162, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 162, and a VL comprising an amino acid sequence according to SEQ ID NO: 201, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 201;ee) a VH comprising an amino acid sequence according to SEQ ID NO: 163, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 163, and a VL comprising an amino acid sequence according to SEQ ID NO: 202, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 202;ff) a VH comprising an amino acid sequence according to SEQ ID NO: 164, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 164, and a VL comprising an amino acid sequence according to SEQ ID NO: 203, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 203;gg) a VH comprising an amino acid sequence according to SEQ ID NO: 165, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 165, and a VL comprising an amino acid sequence according to SEQ ID NO: 204, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 204;hh) a VH comprising an amino acid sequence according to SEQ ID NO: 166, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 166, and a VL comprising an amino acid sequence according to SEQ ID NO: 205, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 205;ii) a VH comprising an amino acid sequence according to SEQ ID NO: 167, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 167, and a VL comprising an amino acid sequence according to SEQ ID NO: 206, or an30MF-363630230Attorney Docket No. 22419-20012.40amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 206;jj) a VH comprising an amino acid sequence according to SEQ ID NO: 168, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 168, and a VL comprising an amino acid sequence according to SEQ ID NO: 207, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 207;kk) a VH comprising an amino acid sequence according to SEQ ID NO: 169, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 169, and a VL comprising an amino acid sequence according to SEQ ID NO: 208, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 208;ll) a VH comprising an amino acid sequence according to SEQ ID NO: 170, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 170, and a VL comprising an amino acid sequence according to SEQ ID NO: 209, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 209;mm) a VH comprising an amino acid sequence according to SEQ ID NO: 171, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 171, and a VL comprising an amino acid sequence according to SEQ ID NO: 210, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 210;nn) a VH comprising an amino acid sequence according to SEQ ID NO: 172, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 172, and a VL comprising an amino acid sequence according to SEQ ID NO: 211, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 211; oroo) a VH comprising an amino acid sequence according to SEQ ID NO: 173, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 173, and a VL comprising an amino acid sequence according to SEQ ID NO: 212, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 212.

[0048] In some embodiments according to any of the embodiments described above, the antibody comprises a Fc domain comprising one or more modifications that reduces binding 31MF-363630230Attorney Docket No. 22419-20012.40to an Fc receptor, reduces binding to complement component Cl q, or reduces binding to an Fc receptor and reduces binding to complement component Cl q.

[0049] In some embodiments according to any of the embodiments described above, the antibody comprises a Fc domain comprising the amino acid modifications L234A / L235A (LALA), L234A / L235A / P329A (LALAPA), L234A / L235A / P329G (LALAPG), L234A / L235A / P329S (LALAPS).

[0050] In some embodiments according to any of the embodiments described above, the antibody or the antigen-binding fragment thereof binds to human DDR1 with an affinity of 10’6M to 10’10M.

[0051] Described herein, in certain embodiments, are immunoconjugates having Formula (I),Ab-[S-L1-L2-L3-L4-L5-L6-L7-D]n(I)wherein:Ab is an antibody or an antigen-binding fragment thereof that binds Discoidin Domain Receptor 1 (DDR1), comprising:a heavy chain variable region (VH) comprising the amino acid sequence according to SEQ ID NO: 164; anda light chain variable region (VL) comprising the amino acid sequence according to SEQ ID NO: 203;S is a sulfur atom of a cysteine of the antibody or the antigen-binding fragment thereof;L1is O;L2is absent;L3is -(CH2)n1-C(=O)-;n1is the integer 2 or 5;L4is gly-gly-phe-gly;L5is -[NH(CH2)n2]n3-;n2is the integer 1;n3is the integer 1;L6is absent;32MF-363630230Attorney Docket No. 22419-20012.40L7is absent;D has the structure:OH O 5and n is 8.

[0052] Described herein, in certain embodiments, are immunoconjugates having Formula (I),Ab-[S-L1-L2-L3-L4-L5-L6-L7-D]n(I)wherein:Ab is an antibody or an antigen-binding fragment thereof that binds Discoidin Domain Receptor 1 (DDR1), comprising:a heavy chain variable region (VH) comprising the amino acid sequence according to SEQ ID NO: 153; anda light chain variable region (VL) comprising the amino acid sequence according to SEQ ID NO: 192;S is a sulfur atom of a cysteine of the antibody or the antigen-binding fragment thereof;L1is O;L2is absent;L3is -(CH2)n1-C(=O)-;n1is the integer 2 or 5;L4is gly-gly-phe-gly;L5is -[NH(CH2)n2]n3-;n2is the integer 1;33MF-363630230Attorney Docket No. 22419-20012.40n3is the integer 1;L6is absent;L7is absent;D has the structure:OH O 5and n is 8.

[0053] In some embodiments according to any of the embodiments described above, n1is the integer 2.

[0054] In some embodiments according to any of the embodiments described above, n1is the integer 5.

[0055] Described herein, in certain embodiments, are polynucleotides encoding any of the antibodies or the antigen-binding fragments thereof described herein, or the antibody or the antigen-binding fragment thereof of any of the immunoconjugates described herein.

[0056] Described herein, in certain embodiments, are expression vectors comprising any of the polynucleotides described herein.

[0057] Described herein, in certain embodiments, are cells comprising any of the expression vectors described herein.

[0058] Described herein, in certain embodiments, are cells capable of producing any of the antibodies or the antigen-binding fragments thereof described herein or polypeptide components of any of the immunoconjugates described herein.

[0059] Described herein, in certain embodiments, are pharmaceutical compositions comprising any of the antibodies or the antigen-binding fragments thereof described herein or any of the immunoconjugates described herein, and a pharmaceutically acceptable excipient, salt, carrier, or diluent.

[0060] Described herein, in certain embodiments, are pharmaceutical compositions for use in modulating the immune system by inhibiting binding to DDR1.34MF-363630230Attorney Docket No. 22419-20012.40

[0061] Described herein, in certain embodiments, are pharmaceutical compositions for use in treating cancer characterized by expression of DDR1 in a subject.

[0062] Described herein, in certain embodiments, are methods of treating cancer characterized by expression of DDR1 comprising administering a therapeutically effective amount of any of the antibodies or the antigen-binding fragments thereof described herein or any of the immunoconjugates described herein to a subject in need thereof.

[0063] In some embodiments according to any of the embodiments described above, the method further comprises administering an additional anti-cancer therapy selected from surgery, chemotherapy, radiotherapy, and immunotherapy.

[0064] In some embodiments according to any of the embodiments described above, the method further comprises administering to the subject an immune-modulator, activated lymphocyte cell, kinase inhibitor, or a chemotherapeutic agent.

[0065] In some embodiments according to any of the embodiments described above, the cancer is a solid tumor.

[0066] In some embodiments according to any of the embodiments described above, the cancer is colon cancer, pancreatic cancer, prostate cancer, breast cancer, head and neck squamous cell carcinoma, head and neck cancer, renal cancer, melanoma, colorectal cancer, diffuse large B cell lymphoma (DLBCL), uterine cancer, lung cancer, squamous non- small cell lung cancer, non- small cell lung cancer adenocarcinoma, ovarian cancer, skin cancer, bladder cancer, urothelial cancer, thyroid cancer, cervical cancer, kidney cancer, brain cancer, central nervous system (CNS) or peripheral nervous system (PNS) cancer, stomach cancer, gastric cancer, esophageal cancer, testicular cancer, liver cancer, hepatocellular cancer, lymphoma, sarcoma, and soft tissue cancer.

[0067] In some embodiments according to any of the embodiments described above, the breast cancer is triple negative breast cancer.

[0068] Described herein, in certain embodiments, are methods of diagnosing or prognosing cancer in a subject, the method comprising determining expression level of DDR1 in a biological samples using any of the antibodies or the antigen-binding fragments thereof described herein or any of the immunoconjugates described herein.

[0069] Described herein, in certain embodiments, are uses of an effective amount of any of the antibodies or the antigen-binding fragments thereof described herein or any of the immunoconjugates described herein for treating cancer in a subject in need thereof.

[0070] In some embodiments according to any of the embodiments described above, the cancer is a solid tumor.35MF-363630230Attorney Docket No. 22419-20012.40

[0071] In some embodiments according to any of the embodiments described above, the cancer is colon cancer, pancreatic cancer, prostate cancer, breast cancer, head and neck squamous cell carcinoma, head and neck cancer, renal cancer, melanoma, colorectal cancer, DLBCL, uterine cancer, lung cancer, squamous non-small cell lung cancer, non-small cell lung cancer adenocarcinoma, ovarian cancer, skin cancer, bladder cancer, urothelial cancer, thyroid cancer, cervical cancer, kidney cancer, brain cancer, CNS or PNS cancer, stomach cancer, gastric cancer, esophageal cancer, testicular cancer, liver cancer, hepatocellular cancer, lymphoma, sarcoma, and soft tissue cancer.

[0072] In some embodiments according to any of the embodiments described above, the breast cancer is triple negative breast cancer.

[0073] Described herein, in certain embodiments, are kits comprising any of the antibodies or the antigen-binding fragments thereof described herein or any of the immunoconjugates described herein and instructions for use.

[0074] Described herein, in certain embodiments, are compositions comprising a plurality of any of the immunoconjugates described herein, wherein the average n of the plurality of the immunoconjugates is a number from 1 to 10.BRIEF DESCRIPTION OF THE DRAWINGS

[0075] FIG. 1 depicts thermal stability data of the antibodies as assessed by differential scanning calorimetry.

[0076] FIG. 2 depicts stability of the antibodies after multiple rounds of freezing and thawing as determined by SEC analysis.

[0077] FIGs. 3A-3B depict quantification of anti-DDRl antibodies bound to cells described herein.

[0078] FIGs. 4A-4B depict internalization of anti-DDRl ADCs described herein.

[0079] FIGs. 5A-5B depict in vitro cytotoxicity data of anti-DDRl ADCs described herein.

[0080] FIG. 6A depicts expression of DDR1 in tumors by immunohistochemistry scoring.

[0081] FIG. 6B depicts immunohistochemistry images. Arrows point towards tumor cells with positive expression of DDR1 at high or moderate levels.

[0082] FIG. 6C depicts expression of DDR1 in tumors by immunohistochemistry scoring.

[0083] FIGs. 7A-7F depict in vivo tumor control of anti-DDRl ADCs including Fc-region modification.

[0084] FIGs. 8A-8B depict in vivo tumor control of anti-DDRl ADCs described herein for efficacy study.36MF-363630230Attorney Docket No. 22419-20012.40

[0085] FIGs. 9A-9B depict in vivo tumor control of anti-DDRl ADCs described herein.

[0086] FIGs. 10A-10B depict in vivo tumor control of anti-DDRl ADCs described herein using an alternate linker.

[0087] FIGs 11A-11B depict in vivo tumor control of an anti-DDRl ADC with multiple drug-antibody ratios.

[0088] FIGs. 12A-12C depicts in vivo tumor control of anti-DDRl antibody compared to an anti-DDRl ADC.

[0089] FIG. 13A depicts a graph of MDCK II cell permeability of payload with Formula (II) as compared to exatecan, YL0014, tirumotecan, rezetecan, A- 1743332, and deruxtecan (DXd).

[0090] FIG. 13B depicts a graph showing TOPI -mediated DNA relaxation activity of payload with Formula (II) to deruxtecan (DXd).

[0091] FIG. 13C depicts a schema and data relating to determination of in vitro bystander activity of payload with Formula (II) and deruxtecan (DXd) in a co-culture model using NCI-11446 cells engineered to express either TROP2 or luciferase.DETAILED DESCRIPTION

[0092] To facilitate an understanding of the present disclosure, a number of terms and phrases are defined below.

[0093] As used herein, the singular forms “a,” “an,” and “the” include plural referents unless the content dictates otherwise. Thus, for example, reference to “an antibody” optionally includes a combination of two or more such molecules and the like.

[0094] The term “about,” as used herein, refers to the usual error range for the respective value readily known to the skilled person in this technical field; for example, ± 20%, ± 10%, or ± 5%, are within the intended meaning of the recited value.

[0095] As used herein, the term “antibody” means an isolated or recombinant binding agent that comprises the necessary variable region sequences to specifically bind an antigenic epitope. Therefore, an “antibody” as used herein is any form of an antibody of any class or subclass or fragment thereof that exhibits the desired biological activity, e.g., binding a specific target antigen. Thus, it is used in the broadest sense and specifically covers a monoclonal antibody (including full-length monoclonal antibodies), human antibodies, chimeric antibodies, nanobodies (Nbs), minibodies, small immunoproteins (SIPs), variable new antigen receptors (VNARs), diabodies, multispecific antibodies (e.g., bispecific antibodies), antibody fragments including but not limited to scFv, Fab, VHH, and the like so 37MF-363630230Attorney Docket No. 22419-20012.40long as they exhibit the desired biological activity. In general, antibodies are multimeric proteins that contain four polypeptide chains. Two of the polypeptide chains are called immunoglobulin heavy chains (H chains), and two of the polypeptide chains are called immunoglobulin light chains (L chains). The immunoglobulin heavy and light chains are connected by an interchain disulfide bond. The immunoglobulin heavy chains are connected by interchain disulfide bonds. A light chain consists of one variable region (VL) and one constant region (CL). The heavy chain consists of one variable region (VH) and at least three constant regions (CHI, CH2 and CH3). The variable regions determine the binding specificity of the antibody. Each variable region contains three hypervariable regions known as complementarity determining regions (CDRs) flanked by four relatively conserved regions known as framework regions (FRs). The extent of the FRs and CDRs has been defined (Kabat, E. A., et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U. S. Department of Health and Human Services, NIH Publication No. 91-3242; and Chothia, C. et al. (1987) J. Mol. Biol. 196:901-917). The three CDRs in each variable region (e.g., light chain variable region or heavy chain variable region, with six CDRs total in a typical antibody format), referred to as CDR1, CDR2, and CDR3, collectively contribute to antibody binding specificity. Naturally occurring antibodies have been used as starting material for engineered antibodies, such as chimeric antibodies and humanized antibodies. Examples of antibodies that have been modified or engineered include chimeric antibodies, humanized antibodies, and multispecific antibodies (e.g., bispecific antibodies). An example of a chemically conjugated antibody is an antibody conjugated to a toxin moiety.

[0096] “Antibody fragments” comprise a portion of an intact antibody, for example, the antigen-binding or variable region of the intact antibody. Examples of antibody fragments include Fab, Fab’, F(ab’)2, and Fv fragments; diabodies; linear antibodies (e.g., Zapata et al., Protein Eng. 8(10): 1057-1062 (1995)); single-chain antibody molecules (e.g., scFv); and multispecific antibodies formed from antibody fragments. Papain digestion of antibodies produces two identical antigen-binding fragments, called “Fab” fragments, each with a single antigen-binding site, and a residual “Fc” fragment, a designation reflecting the ability to crystallize readily. Pepsin treatment yields an F(ab’)2 fragment with two antigen combining sites and is still capable of cross-linking antigen.

[0097] As used herein, the term “anti-DDRl antibody”, “antibody that binds DDR1,” “antibody or antigen-binding fragment thereof that binds DDR1,” “antibody that targets DDR1,” or “DDR 1 -targeting antibody,” with respect to an antibody, refers to an antibody or antigen binding fragment that binds preferentially to DDR1.38MF-363630230Attorney Docket No. 22419-20012.40

[0098] As used herein, “V-region” refers to an antibody variable region domain comprising the segments of Framework 1, CDR1, Framework 2, CDR2, and Framework 3, including CDR3 and Framework 4. The heavy chain V-region, VH, is a consequence of the rearrangement of a V-gene (HV), a D-gene (HD), and a J-gene (HJ), in what is termed V(D)J recombination during B-cell differentiation. The light chain V-region, VL, is a consequence of the rearrangement of a V-gene (LV) and a J-gene (LJ).

[0099] As used herein, “complementarity-determining region (CDR)” refers to the three hypervariable regions (HVRs) in each chain that interrupt the four “framework” regions established by the light and heavy chain variable regions. The CDRs are the primary contributors to binding to an epitope of an antigen. The CDRs of each chain are referred to as CDR1, CDR2, and CDR3, numbered sequentially starting from the N-terminus, and are also identified by the chain in which the CDR is located. Thus, a VH CDR3 (CDR3) is in the variable domain of the heavy chain of the antibody in which it is found, whereas a VL CDR3 (CDR3) is the CDR3 from the variable domain of the light chain of the antibody in which it is located. The term “CDR” is used interchangeably with “HVR” when referring to CDR sequences.

[0100] The amino acid sequences of the CDRs and framework regions can be determined using various well-known definitions in the art, e.g., Kabat, Chothia, international ImMunoGeneTics database (IMGT), and AbM (see, e.g., Chothia & Lesk, 1987, Canonical structures for the hypervariable regions of immunoglobulins. J. Mol. Biol. 196, 901-917; Chothia C. et al., 1989, Conformations of immunoglobulin hypervariable regions. Nature 342, 877-883; Chothia C. et al., 1992, Structural repertoire of the human VH segments J. Mol. Biol. 227, 799-817; Al-Lazikani et al., J. Mol. Biol. 1997, 273(4)). Definitions of antigen combining sites are also described in the following: Ruiz et al., IMGT, the international ImMunoGeneTics database. Nucleic Acids Res., 28, 219-221 (2000); and Lefranc, M.-P. IMGT, the international ImMunoGeneTics database. Nucleic Acids Res. Jan l;29(l):207-9 (2001); MacCallum et al., Antibody-antigen interactions: Contact analysis and binding site topography, J. Mol. Biol., 262 (5), 732-745 (1996); and Martin et al, Proc. Natl Acad. Sci. USA, 86, 9268-9272 (1989); Martin et al., Methods Enzymol., 203, 121-153, (1991); Pedersen et al., Immunomethods, 1, 126, (1992); and Rees et al., In Sternberg M. J. E. (ed.), Protein Structure Prediction. Oxford University Press, Oxford, 141-172 1996).Reference to CDRs as determined by Kabat numbering is based, for example, on Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National39MF-363630230Attorney Docket No. 22419-20012.40Institute of Health, Bethesda, MD (1991)). Chothia CDRs are determined as defined by Chothia (see, e.g., Chothia and Lesk J. Mol. Biol. 196:901-917 (1987)).

[0101] Table A provides the positions of CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2, and CDR-H3 as identified by the Kabat and Chothia schemes. For CDR-H1, residue numbering is provided using both the Kabat and Chothia numbering schemes. CDRs may be assigned, for example, using antibody numbering software, such as Abnum, available at www.bioinf.org.uk / abs / abnum / , and described in Abhinandan and Martin (2008) Immunology, 45:3832-3839, incorporated by reference in its entirety.Table A. Residues in CDRs according to Kabat and Chothia numbering schemes. CDR Kabat ChothiaLI L24-L34 L24-L34L2 L50-L56 L50-L56L3 L89-L97 L89-L97Hl (Kabat Numbering) H31-H35B H26-H32 or H34*Hl (Chothia Numbering) H31-H35 H26-H32H2 H50-H65 H52-H56H3 H95-H102 H95-H102* The C -terminus of CDR-H1, when numbered using the Kabat numbering convention, varies between H32 and H34, depending on the length of the CDR.

[0102] The “EU numbering scheme” is generally used when referring to a residue in an antibody heavy chain constant region (e.g., as reported in Kabat et al., supra). Unless stated otherwise, the EU numbering scheme is used to refer to residues in antibody heavy chain constant regions described herein.

[0103] An “Fc region” refers to the constant region of an antibody excluding the first constant region immunoglobulin domain. Thus, e.g., for human immunoglobulins, “Fc” refers to the last two constant region immunoglobulin domains of IgA, IgD, and IgG, and the last three constant region immunoglobulin domains of IgE and IgM, and the flexible hinge N-terminal to these domains. For IgA and IgM, Fc may include the J chain. For IgG, Fc comprises immunoglobulin domains Cy2 and Cy3 and the hinge between Cyl and Cy2. It is understood in the art that the boundaries of the Fc region may vary, however, the human IgG heavy chain Fc region is usually defined to comprise residues C226 or P230 to its carboxylterminus, using the numbering according to the EU index as in Kabat et al. (1991, NIH Publication 91-3242, National Technical Information Service, Springfield, Va.). The term “Fc region” may refer to this region in isolation or this region in the context of an antibody or40MF-363630230Attorney Docket No. 22419-20012.40antibody fragment. “Fc region” includes naturally occurring allelic variants of the Fc region as well as modified Fc regions, e.g., that are modified to modulate effector function or other properties such as pharmacokinetics, stability or production properties of an antibody. Fc regions also include variants that do not exhibit alterations in biological function. For example, one or more amino acids can be deleted from the N-terminus or C-terminus of the Fc region of an immunoglobulin without substantial loss of biological function. Such variants can be selected according to general rules known in the art to have minimal effect on activity (see, e.g., Bowie et al., Science 247:306-1310, 1990). For example, for IgG4 antibodies, a single amino acid substitution (S228P according to Kabat numbering; designated IgG4Pro) may be introduced to abolish the heterogeneity observed in recombinant IgG4 antibodies (see, e.g., Angal et al., Mol Immunol 30:105-108, 1993).

[0104] An “EC50” as used herein refers to the half-maximal effective concentration, which is the concentration of an antibody that induces a response (signal generated in engagement assay) halfway between the baseline and maximum after a specified exposure time. In some embodiments, the “fold over EC50” is determined by dividing the EC50 of a reference antibody by the EC50 of the test antibody.

[0105] The term “equilibrium dissociation constant” abbreviated (KD), refers to the dissociation rate constant (kd, time-1) divided by the association rate constant (ka, time-1M-1). Equilibrium dissociation constants can be measured using any method.

[0106] The term “monovalent molecule” refers to a molecule having one antigen-binding site, e.g., a Fab or scFv.

[0107] The term “bivalent molecule” as used herein, refers to a molecule having two antigenbinding sites. In some embodiments, a bivalent molecule of the present disclosure is a bivalent antibody or a bivalent fragment thereof. In some embodiments, a bivalent molecule of the present disclosure is a bivalent antibody. In some embodiments, a bivalent molecule of the present disclosure is an IgG. In general, monoclonal antibodies have a bivalent basic structure. IgG and IgE have only one bivalent unit, while IgA and IgM consist of multiple bivalent units (2 and 5, respectively) and thus have higher valencies. This bivalency increases the avidity of antibodies for antigens.

[0108] The terms “monovalent binding” or “monovalently binds to” as used herein refer to the binding of one antigen-binding site to its antigen.

[0109] The terms “bivalent binding” or “bivalently binds to” refer to the binding of both antigen-binding sites of a bivalent molecule to its antigen. In some embodiments, both antigen-binding sites of a bivalent molecule share the same antigen specificity.41MF-363630230Attorney Docket No. 22419-20012.40

[0110] The term “valency” refers to the number of different binding sites of an antibody for an antigen. A monovalent antibody comprises one binding site for an antigen. A bivalent antibody comprises two binding sites for the same antigen.

[0111] The term “avidity” in the context of antibody binding to an antigen refers to the combined binding strength of multiple binding sites of the antibody. Thus, “bivalent avidity” refers to the combined strength of two binding sites.

[0112] The terms “identical” or percent “identity,” in the context of two or more polynucleotide or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues that are the same (e.g., 100% identity) or have a specified percentage of nucleotides or amino acid residues are the same (e.g., at least 70%, at least 75%, at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher sequence identity; or 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity)) identity over a specified region, e.g., the length of the two sequences, when compared and aligned for maximum correspondence over a comparison window or designated region. Alignment for purposes of determining percent amino acid sequence identity can be performed in various methods, including those using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Examples of algorithms that are suitable for determining percent sequence identity and sequence similarity include the BLAST 2.0 algorithms, which are described in Altschul et al., Nuc. Acids Res. 25:3389-3402 (1977) and Altschul et al., J. Mol. Biol. 215:403-410 (1990). Thus, for purposes of this disclosure, BLAST 2.0 can be used with the default parameters to determine percent sequence identity.

[0113] The terms “corresponding to,” “determined with reference to,” or “numbered with reference to” when used in the context of the identification of a given amino acid residue in a polypeptide sequence, refers to the position of the residue of a specified reference sequence when the given amino acid sequence is maximally aligned and compared to the reference sequence. The polypeptide that is aligned to the reference sequence need not be the same length as the reference sequence.

[0114] A “conservative” substitution refers to a substitution of an amino acid such that charge, polarity, hydropathy (hydrophobic, neutral, or hydrophilic), and / or size of the side group chain is maintained. Illustrative sets of amino acids that may be substituted for one another include (i) positively-charged amino acids Lys and Arg; and His at pH of about 6; (ii) negatively charged amino acids Glu and Asp; (iii) aromatic amino acids Phe, Tyr and Trp;42MF-363630230Attorney Docket No. 22419-20012.40(iv) nitrogen ring amino acids His and Trp; (v) aliphatic hydrophobic amino acids Ala, Vai, Leu and He; (vi) hydrophobic sulfur-containing amino acids Met and Cys, which are not as hydrophobic as Vai, Leu, and He; (vii) small polar uncharged amino acids Ser, Thr, Asp, and Asn (viii) small hydrophobic or neutral amino acids Gly, Ala, and Pro; (ix) amide-comprising amino acids Asn and Gin; and (xi) beta-branched amino acids Thr, Vai, and lie. Reference to the charge of an amino acid in this paragraph refers to the charge at pH 6-7.

[0115] The terms “polynucleotide,” “oligonucleotide,” and “nucleic acid” are used interchangeably to refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof, either in single-, double-, or multi- stranded form. Contemplated polynucleotides include a gene or fragment thereof.Exemplary polynucleotides include, but are not limited to, DNA, RNA, coding or non-coding regions of a gene or gene fragment, loci (locus) defined from linkage analysis, exons, introns, messenger RNA (mRNA), transfer RNA (tRNA), ribosomal RNA (rRNA), short interfering RNA (siRNA), short-hairpin RNA (shRNA), micro-RNA (miRNA), ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, cell-free polynucleotides including cell-free DNA (cfDNA) and cell-free RNA (cfRNA), nucleic acid probes, and primers. In a polynucleotide when referring to a T, a T means U (Uracil) in RNA and T (Thymine) in DNA. A polynucleotide can be exogenous or endogenous to a cell and / or exist in a cell-free environment. The term polynucleotide encompasses modified polynucleotides (e.g., altered backbone, sugar, or nucleobase). H present, modifications to the nucleotide structure are imparted before or after assembly of the polymer. Non-limiting examples of modifications include: 5-bromouracil, peptide nucleic acid, xeno nucleic acid, morpholinos, locked nucleic acids, glycol nucleic acids, threose nucleic acids, dideoxynucleotides, cordycepin, 7-deaza-GTP, fluorophores (e.g., rhodamine or fluorescein linked to the sugar), thiol-containing nucleotides, biotin-linked nucleotides, fluorescent base analogs, CpG islands, methyl-7-guanosine, methylated nucleotides, inosine, thiouridine, pseudouridine, dihydrouridine, queuosine, and wyosine. The sequence of nucleotides may be interrupted by non-nucleotide components.

[0116] The term “vector,” as used herein, refers to a nucleic acid molecule capable of propagating another nucleic acid to which it is linked. The term includes the vector as a selfreplicating nucleic acid structure as well as the vector incorporated into the genome of a host cell into which it has been introduced. A “vector” as used herein refers to a recombinant construct in which a nucleic acid sequence of interest is inserted into the vector. Certain43MF-363630230Attorney Docket No. 22419-20012.40vectors can direct the expression of nucleic acids to which they are operatively linked. Such vectors are referred to herein as “expression vectors”.

[0117] A “substitution” denotes the replacement of one or more amino acids or nucleotides by different amino acids or nucleotides, respectively.

[0118] An “isolated” nucleic acid refers to a nucleic acid molecule that has been separated from a component of its natural environment. An isolated nucleic acid includes a nucleic acid molecule contained in cells that ordinarily contain the nucleic acid molecule, but the nucleic acid molecule is present extrachromosomally or at a chromosomal location that is different from its natural chromosomal location.

[0119] “Isolated nucleic acid encoding an antibody or fragment thereof’ refers to one or more nucleic acid molecules encoding antibody heavy or light chains (or fragments thereof), including such nucleic acid molecule(s) in a single vector or separate vectors, and such nucleic acid molecule(s) present at one or more locations in a host cell.

[0120] The terms “host cell,” “host cell line,” and “host cell culture” are used interchangeably and refer to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells. Thus, a host cell is a recombinant host cell and includes the primary transformed cell and progeny derived therefrom without regard to the number of passages.

[0121] The term “cancer cell” or “tumor cell” as used herein refers to a neoplastic cell. The term includes cells from tumors that are benign as well as malignant. Neoplastic transformation is associated with phenotypic changes of the tumor cell relative to the cell type from which it is derived. The changes can include loss of contact inhibition, morphological changes, and unregulated cell growth.

[0122] The terms “inhibiting growth of a tumor” and “inhibiting growth of a cancer” are interchangeable and refer to slowing growth and / or reducing the cancer cell burden of a patient that has cancer. “Inhibiting growth of a cancer” thus includes killing cancer cells, as well as decreasing the rate of tumor growth, tumor size, invasion, and / or metastasis by direct or indirect effects on tumor cells.

[0123] As used herein, the terms “treatment,” “treating,” and the like, in some embodiments, refer to administering an agent, or carrying out a procedure, for the purposes of obtaining an effect. The effect may be prophylactic in terms of completely or partially preventing a disease or symptom thereof and / or may be therapeutic in terms of affecting a partial or complete cure for a disease and / or symptoms of the disease. “Treatment,” as used herein, may include treatment of a disease or disorder (e.g., cancer) in a mammal, particularly in a human, and 44MF-363630230Attorney Docket No. 22419-20012.40includes: (a) preventing the disease or a symptom of a disease from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it (e.g., including diseases that may be associated with or caused by a primary disease; (b) inhibiting the disease, i.e., arresting its development; and (c) relieving the disease, i.e., causing regression of the disease. Treating may refer to any indicia of success in the treatment or amelioration or prevention of a cancer, including any objective or subjective parameter such as abatement; remission; diminishing of symptoms; or making the disease condition more tolerable to the patient; slowing in the rate of degeneration or decline; or making the final point of degeneration less debilitating. The treatment or amelioration of symptoms is based on one or more objective or subjective parameters; including the results of an examination by a physician. Accordingly, the term “treating” includes the administration of the compounds or agents of the present disclosure to prevent, delay, alleviate, arrest or inhibit development of the symptoms or conditions associated with diseases (e.g., cancer). The term "therapeutic effect" refers to the reduction, elimination, or prevention of the disease, symptoms of the disease, or side effects of the disease in the subject.

[0124] The terms “subject,” “recipient,” “individual,” “host,” and “patient,” are used interchangeably herein and in some embodiments, refer to any mammalian subject for whom diagnosis, treatment, or therapy is desired, particularly humans. “Mammal” for purposes of treatment refers to any animal classified as a mammal, including humans, domestic and farm animals, and laboratory, zoo, sports, or pet animals, such as dogs, horses, cats, cows, sheep, goats, pigs, mice, rats, rabbits, guinea pigs, monkeys etc. In some embodiments, the mammal is human. None of these terms require the supervision of medical personnel.

[0125] A “variant” of a reference antibody refers to an antibody that typically differs from the reference antibody in one or more substitutions, deletions, additions, and / or insertions in the amino acid sequence of the heavy and / or light chain.ANTI-DDR1 ANTIBODIES

[0126] Described herein, in certain embodiments, are antibodies and antigen-binding fragments thereof that bind DDR1 (i.e., anti-DDRl antibodies) comprising a) a heavy chain variable region (VH) comprising (i) a CDR1 having an amino acid sequence according to any one of SEQ ID NOs: 1-23, (ii) a CDR2 having an amino acid sequence according to any one of SEQ ID NOs: 24-46, and (iii) a CDR3 having an amino acid sequence according to any one of SEQ ID NOs: 47-69; and b) a light chain variable region (VL) comprising (i) a CDR1 having an amino acid sequence according to any one of SEQ ID NOs: 70-90, (ii) a CDR245MF-363630230Attorney Docket No. 22419-20012.40having an amino acid sequence according to any one of SEQ ID NOs: 91-111, and (iii) a CDR3 having an amino acid sequence according to any one of SEQ ID NOs: 112-132.

[0127] In some embodiments, an anti-DDRl antibody comprises a CDR1 having an amino acid sequence according to SEQ ID NOs: 1-23 or a variant CDR1 in which 1, 2, 3, 4, or 5 amino acids are substituted relative to the sequence; a CDR2 having an amino acid sequence according to SEQ ID NOs: 24-46, or a variant CDR2 in which 1, 2, 3, 4, or 5 amino acids are substituted relative to the sequence; and a CDR3 having an amino acid sequence according SEQ ID NOs: 47-69 or a variant CDR3 in which 1, 2, 3, 4, or 5 amino acids are substituted relative to the sequence. In some embodiments, an anti-DDRl antibody comprises a light chain variable region comprising: a CDR1 having an amino acid sequence according to SEQ ID NOs: 70-90, or a variant CDR1 in which 1, 2, 3, 4, or 5 amino acids are substituted relative to the sequence; a CDR2 having an amino acid sequence according to SEQ ID NOs: 91-111, or variant CDR2 in which 1, 2, or 3 amino acids are substituted relative to the sequence; and a CDR3 having an amino acid sequence according to SEQ ID NOs: 112-132, or a variant CDR3 in which 1, 2, 3, 4, or 5 amino acids are substituted relative to the sequence.

[0128] In some embodiments, the anti-DDRl antibodies comprise a) a heavy chain variable region (VH) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 1, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 24, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 47; and b) a light chain variable region (VL) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 70, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 91, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 112.

[0129] In some embodiments, the anti-DDRl antibodies comprise a) a heavy chain variable region (VH) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 2, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 25, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 48; and b) a light chain variable region (VL) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 71, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 92, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 113.

[0130] In some embodiments, the anti-DDRl antibodies comprise a) a heavy chain variable region (VH) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 3, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 26, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 49; and b) a light chain 46MF-363630230Attorney Docket No. 22419-20012.40variable region (VL) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 72, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 93, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 114.

[0131] In some embodiments, the anti-DDRl antibodies comprise a) a heavy chain variable region (VH) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 4, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 27, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 50; and b) a light chain variable region (VL) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 73, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 94, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 115.

[0132] In some embodiments, the anti-DDRl antibodies comprise a) a heavy chain variable region (VH) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 5, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 28, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 51; and b) a light chain variable region (VL) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 74, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 95, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 116.

[0133] In some embodiments, the anti-DDRl antibodies comprise a) a heavy chain variable region (VH) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 6, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 29, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 52; and b) a light chain variable region (VL) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 75, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 96, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 117.

[0134] In some embodiments, the anti-DDRl antibodies comprise a) a heavy chain variable region (VH) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 7, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 30, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 53; and b) a light chain variable region (VL) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 76, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 97, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 118.

[0135] In some embodiments, the anti-DDRl antibodies comprise a) a heavy chain variable region (VH) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 8, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 31, and (iii) a 47MF-363630230Attorney Docket No. 22419-20012.40CDR3 having an amino acid sequence according to SEQ ID NO: 54; and b) a light chain variable region (VL) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 77, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 98, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 119.

[0136] In some embodiments, the anti-DDRl antibodies comprise a) a heavy chain variable region (VH) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 9, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 32, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 55; and b) a light chain variable region (VL) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 78, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 99, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 120.

[0137] In some embodiments, the anti-DDRl antibodies comprise a) a heavy chain variable region (VH) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 10, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 33, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 56; and b) a light chain variable region (VL) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 79, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 100, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 121.

[0138] In some embodiments, the anti-DDRl antibodies comprise a) a heavy chain variable region (VH) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 11, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 34, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 57; and b) a light chain variable region (VL) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 80, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 101, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 122.

[0139] In some embodiments, the anti-DDRl antibodies comprise a) a heavy chain variable region (VH) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 12, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 35, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 58; and b) a light chain variable region (VL) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 81, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 102, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 123.

[0140] In some embodiments, the anti-DDRl antibodies comprise a heavy chain variable region (VH) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID 48MF-363630230Attorney Docket No. 22419-20012.40NO: 13, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 36, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 59.

[0141] In some embodiments, the anti-DDRl antibodies comprise a) a heavy chain variable region (VH) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 14, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 37, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 60; and b) a light chain variable region (VL) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 213, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 214, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 215.

[0142] In some embodiments, the anti-DDRl antibodies comprise a) a heavy chain variable region (VH) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 15, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 38, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 61; and b) a light chain variable region (VL) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 82, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 103, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 124.

[0143] In some embodiments, the anti-DDRl antibodies comprise a) a heavy chain variable region (VH) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 16, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 39, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 62; and b) a light chain variable region (VL) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 83, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 104, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 125.

[0144] In some embodiments, the anti-DDRl antibodies comprise a) a heavy chain variable region (VH) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 17, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 40, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 63; and b) a light chain variable region (VL) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 84, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 105, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 126.

[0145] In some embodiments, the anti-DDRl antibodies comprise a) a heavy chain variable region (VH) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 18, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 41, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 64; and b) a light chain 49MF-363630230Attorney Docket No. 22419-20012.40variable region (VL) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 85, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 106, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 127.

[0146] In some embodiments, the anti-DDRl antibodies comprise a) a heavy chain variable region (VH) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 19, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 42, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 65; and b) a light chain variable region (VL) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 86, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 107, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 128.

[0147] In some embodiments, the anti-DDRl antibodies comprise a) a heavy chain variable region (VH) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 20, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 43, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 66; and b) a light chain variable region (VL) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 87, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 108, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 129.

[0148] In some embodiments, the anti-DDRl antibodies comprise a) a heavy chain variable region (VH) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 21, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 44, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 67; and b) a light chain variable region (VL) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 88, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 109, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 130.

[0149] In some embodiments, the anti-DDRl antibodies comprise a) a heavy chain variable region (VH) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 22, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 45, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 68; and b) a light chain variable region (VL) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 89, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 110, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 131.

[0150] In some embodiments, the anti-DDRl antibodies comprise a) a heavy chain variable region (VH) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 23, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 46, and (iii) a 50MF-363630230Attorney Docket No. 22419-20012.40CDR3 having an amino acid sequence according to SEQ ID NO: 69; and b) a light chain variable region (VL) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 90, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 111, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 132.

[0151] In some embodiments an anti-DDRl antibody comprises a heavy chain variable (VH) region and a light chain variable (VL) region. The VH region has an amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% identical to SEQ ID NOs: 133-173; and comprises a CDR1 having an amino acid sequence according to SEQ ID NOs: 1-23, or the CDR1 of SEQ ID NOs: 1-23 in which 1, 2, 3, 4, or 5 amino acids are substituted; a CDR2 having an amino acid sequence according to SEQ ID NOs: 24-46, or the CDR2 of SEQ ID NOs: 24-46 in which 1, 2, 3, 4, or 5 amino acids are substituted; a CDR3 having an amino acid sequence according to SEQ ID NOs: 47-69 or the CDR3 of SEQ ID NOs: 47-69 in which 1, 2, 3, 4, or 5 amino acids are substituted. The VL region has an amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% identical to SEQ ID NOs: 174-212, and comprises a CDR1 having an amino acid sequence according to SEQ ID NOs: 60-80 or the CDR1 of SEQ ID NOs: 60-80 in which 1, 2, 3, 4, or 5 amino acids are substituted; a CDR2 having an amino acid sequence according to SEQ ID NOs: 91-111, or the CDR2 of SEQ ID NOs: 91-111 in which 1, 2, or 3 amino acids are substituted; a CDR3 having an amino acid sequence according to SEQ ID NOs: 112-132 or the CDR3 of SEQ ID NOs: 112-132 in which 1, 2, 3, 4, or 5 amino acids are substituted.

[0152] In some embodiments, an anti-DDRl antibody of the present disclosure has one, two, or three CDRs of a VL sequence having an amino acid sequence according to a sequence set forth in Table 2. In some embodiments, the anti-DDRl antibody has at least one mutation and no more than 10, 20, 30, 40 or 50 mutations in the VL amino acid sequences compared to a VL sequence set forth in Table 3. In some embodiments, the anti-DDRl antibody has a VL amino acid sequence set forth in Table 3. In some embodiments, the VL amino acid sequence may comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid insertions or deletions compared to a VL sequence set forth in Table 3. In some embodiments, the VL amino acid sequence may comprise a deletion or insertion, e.g., a 1, 2, 3, 4, 5, 6, or 7 amino acid deletion or insertion, relative to a CDR sequence shown in Table 2. In some embodiments, the VL region comprises a CDR1 having 1 or 2 substitutions in relative to a CDR1 sequence shown in Table 2. In some embodiments, a CDR1 has 3, 4, or 5 substitutions relative to a CDR1 sequence shown in Table 2. In some embodiments, the VL region comprises a CDR2 that has 51MF-363630230Attorney Docket No. 22419-20012.401, 2, or 3 substitutions relative to the CDR2 sequence shown in Table 2. In some embodiments, the VL region comprises a CDR3 that has 1, 2, 3, or 4 substitutions relative to a CDR3 sequence shown in Table 2. In some embodiments, an anti-DDRl antibody of the present disclosure comprises a CDR1, CDR2, and CDR3, each having at least 70% identity to a CDR1, CDR2, and CDR3 as shown in Table 2. In some embodiments, an anti-DDRl antibody of the present disclosure comprises a CDR1, CDR2, and CDR3, each having at least 75% identity to a CDR1, CDR2, and CDR3 as shown in Table 2. In some embodiments, an anti-DDRl antibody of the present disclosure comprises a CDR1, CDR2, and CDR3, each having at least 80% identity to a CDR1, CDR2, and CDR3 as shown in Table 2. In some embodiments, an anti-DDRl antibody of the present disclosure comprises a CDR1, CDR2, and CDR3, each having at least 85% identity to a CDR1, CDR2, and CDR3 as shown in Table 2. In some embodiments, an anti-DDRl antibody of the present disclosure comprises a CDR1, CDR2, and CDR3, each having at least 90% identity to a CDR1, CDR2, and CDR3 as shown in Table 2. In some embodiments, an anti-DDRl antibody of the present disclosure comprises a CDR1, CDR2, and CDR3, each having at least 95% identity to a CDR1, CDR2, and CDR3 as shown in Table 2. In some embodiments, an anti-DDRl antibody of the present disclosure comprises a CDR1, CDR2, and CDR3, each having 100% identity to a CDR1, CDR2, and CDR3 as shown in Table 2.

[0153] In some embodiments, an anti-DDRl antibody of the present disclosure has one, two, or three CDRs of a VH sequence (CDRs) having an amino acid sequence according to a sequence set forth in Table 1. In some embodiments, the anti-DDRl antibody has at least one mutation and no more than 10, 20, 30, 40 or 50 mutations in the VH amino acid sequences compared to a VH sequence set forth in Table 3. In some embodiments, the anti-DDRl antibody has a VH amino acid sequence set forth in Table 3. In some embodiments, the VH amino acid sequence may comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid insertions or deletions compared to a VH sequence set forth in Table 3. In some embodiments, the VH amino acid sequence may comprise a deletion or insertion, e.g., a 1, 2, 3, 4, 5, 6, or 7 amino acid deletion or insertion, relative to a CDR sequence shown in Table 1. In some embodiments, the VH region comprises a CDR1 having 1 or 2 substitutions in relative to a CDR1 sequence shown in Table 1. In some embodiments, a CDR1 has 3, 4, or 5 substitutions relative to a CDR1 sequence shown in Table 1. In some embodiments, the VH region comprises a CDR2 that has or 1, 2, or 3; substitutions relative to the CDR2 sequence shown in Table 1. In some embodiments, the VH region comprises a CDR3 that has 1, 2, 3, or 4 substitutions relative to a CDR3 sequence shown in Table 1. In some embodiments, an 52MF-363630230Attorney Docket No. 22419-20012.40anti-DDRl antibody of the present disclosure comprises a CDR1, CDR2, and CDR3, each having at least 70% identity to a CDR1, CDR2, and CDR3 as shown in Table 1. In some embodiments, an anti-DDRl antibody of the present disclosure comprises a CDR1, CDR2, and CDR3, each having at least 75% identity to a CDR1, CDR2, and CDR3 as shown in Table 1. In some embodiments, an anti-DDRl antibody of the present disclosure comprises a CDR1, CDR2, and CDR3, each having at least 80% identity to a CDR1, CDR2, and CDR3 as shown in Table 1. In some embodiments, an anti-DDRl antibody of the present disclosure comprises a CDR1, CDR2, and CDR3, each having at least 85% identity to a CDR1, CDR2, and CDR3 as shown in Table 1. In some embodiments, an anti-DDRl antibody of the present disclosure comprises a CDR1, CDR2, and CDR3, each having at least 90% identity to a CDR1, CDR2, and CDR3 as shown in Table 1. In some embodiments, an anti-DDRl antibody of the present disclosure comprises a CDR1, CDR2, and CDR3, each having at least 95% identity to a CDR1, CDR2, and CDR3 as shown in Table 1. In some embodiments an anti-DDRl antibody of the present disclosure comprises a CDR1, CDR2, and CDR3, each having 100% identity to a CDR1, CDR2, and CDR3 as shown in Table 1.

[0154] The sequences of the anti-DDRl antibodies described herein are shown in Tables 1-6.

[0155] In some embodiments, an anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence at least 70% identical to any one of SEQ ID NOs: 133-173. In some embodiments, an anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence at least 75% identical to any one of SEQ ID NOs: 133-173. In some embodiments, an anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence at least 80% identical to any one of SEQ ID NOs: 133-173. In some embodiments, an anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence at least 85% identical to any one of SEQ ID NOs: 133-173. In some embodiments, an anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence at least 90% identical to any one of SEQ ID NOs: 133-173. In some embodiments, an anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence at least 95% identical to any one of SEQ ID NOs: 133-173. In some embodiments, an anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence at least 96% identical to any one of SEQ ID NOs: 133-173. In some embodiments, an anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence at least 97% identical to any one of SEQ ID NOs: 133-173. In some embodiments, an anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence at least 98% identical to any one of SEQ ID NOs:53MF-363630230Attorney Docket No. 22419-20012.40133-173. In some embodiments, an anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence at least 99% identical to any one of SEQ ID NOs: 133-173. In some embodiments, an anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid identical to any one of SEQ ID NOs: 133-173.

[0156] In some embodiments, an anti-DDRl antibody comprises a light chain variable region comprising an amino acid sequence at least 70% identical to any one of SEQ ID NOs: 174-212. In some embodiments, an anti-DDRl antibody comprises a light chain variable region comprising an amino acid sequence at least 75% identical to any one of SEQ ID NOs: 174-212. In some embodiments, an anti-DDRl antibody comprises a light chain variable region comprising an amino acid sequence at least 80% identical to any one of SEQ ID NOs: 174-212. In some embodiments, an anti-DDRl antibody comprises a light chain variable region comprising an amino acid sequence at least 85% identical to any one of SEQ ID NOs: 174-212. In some embodiments, an anti-DDRl antibody comprises a light chain variable region comprising an amino acid sequence at least 90% identical to any one of SEQ ID NOs: 174-212. In some embodiments, an anti-DDRl antibody comprises a light chain variable region comprising an amino acid sequence at least 95% identical to any one of SEQ ID NOs: 174-212. In some embodiments, an anti-DDRl antibody comprises a light chain variable region comprising an amino acid sequence at least 96% identical to any one of SEQ ID NOs: 174-212. In some embodiments, an anti-DDRl antibody comprises a light chain variable region comprising an amino acid sequence at least 97% identical to any one of SEQ ID NOs: 174-212. In some embodiments, an anti-DDRl antibody comprises a light chain variable region comprising an amino acid sequence at least 98% identical to any one of SEQ ID NOs: 174-212. In some embodiments, an anti-DDRl antibody comprises a light chain variable region comprising an amino acid sequence at least 99% identical to any one of SEQ ID NOs: 174-212. In some embodiments, an anti-DDRl antibody comprises a light chain variable region comprising an amino acid sequence identical to any one of SEQ ID NOs: 174-212.

[0157] In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region (VH) that comprises an amino acid sequence at least 60% (e.g., at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the heavy chain variable region (VH) of an anti-DDRl antibody disclosed in Table 3, and a light chain variable region (VL) that comprises an amino acid sequence at least 60% (e.g., at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%,54MF-363630230Attorney Docket No. 22419-20012.40at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the light chain variable region (VL) of the same anti-DDRl antibody disclosed in Table 3.

[0158] In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to any one of SEQ ID NOs: 133-173; and a light chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to any one of SEQ ID NOs: 174-212. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to any one of SEQ ID NOs: 133-173; and a light chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to any one of SEQ ID NOs: 174-212. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to any one of SEQ ID NOs: 133-173; and a light chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to any one of SEQ ID NOs: 174-212. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to any one of SEQ ID NOs: 133-173; and a light chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to any one of SEQ ID NOs: 174-212. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to any one of SEQ ID NOs: 133-173; and a light chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to any one of SEQ ID NOs: 174-212. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to any one of SEQ ID NOs: 133-173; and a light chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to any one of SEQ ID NOs: 174-212. In some embodiments, the Anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to any one of SEQ ID NOs: 133-173 and a light chain variable region comprising an amino acid sequence having at least 98% sequence 55MF-363630230Attorney Docket No. 22419-20012.40identity with an amino acid sequence according to any one of SEQ ID NOs: 174-212. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according to any one of SEQ ID NOs: 133-173; and a light chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according any one of SEQ ID NOs: 174-212. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence according to any one of SEQ ID NOs: 133-173; and a light chain variable region comprising an amino acid sequence according to any one of SEQ ID NOs: 174-212.

[0159] In some embodiments, the anti-DDRl antibody comprises one, two, three, or four VH framework (FW) region sequences selected from the VH FW region sequences disclosed in Table 5, or a variant thereof comprising up to about 5 (such as about any of 1, 2, 3, 4, or 5) amino acid insertions, deletions, or substitutions, and one, two, three, or four VL FW sequences selected from the VL FW region sequences disclosed in Table 6, or a variant thereof comprising up to about 5 (such as about any of 1, 2, 3, 4, or 5) amino acid insertions, deletions, or substitutions. In some embodiments, the anti-DDRl antibody comprises one, two, three, or four VH FW region sequences selected from the VH FW region sequences disclosed in Table 5, and one, two, three, or four VL FW region sequences selected from the VL FW region sequences disclosed in Table 6.

[0160] In some embodiments, the anti-DDRl antibody comprises a heavy chain (HC) that comprises an amino acid sequence at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) identical to the HC of an anti-DDRl antibody disclosed in Table 4, and a light chain (LC) that comprises an amino acid sequence at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) identical to the LC of the same anti-DDRl antibody disclosed in Table 4.

[0161] In some embodiments, the anti-DDRl antibody comprises a VH comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 133; and a VL comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 174. In some embodiments, the anti-DDRl antibody comprises a VH comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 1, a CDR2 having an amino acid sequence according to SEQ ID NO: 24, and a CDR3 having an amino acid sequence according to SEQ ID NO: 47, and a VL comprising a CDR1 having an amino 56MF-363630230Attorney Docket No. 22419-20012.40acid sequence according to SEQ ID NO: 70, a CDR2 having an amino acid sequence according to SEQ ID NO: 91, and a CDR3 having an amino acid sequence according to SEQ ID NO: 112, and one or more FW region sequences selected from the group consisting of (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 294; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 295; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 296; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 297; (e) a FWL1 comprising an amino acid sequence of SEQ ID NO: 386; (f) a FWL2 comprising an amino acid sequence of SEQ ID NO: 387; (g) a FWL3 comprising an amino acid sequence of SEQ ID NO: 388; and / or (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 389. In some embodiments, the anti-DDRl antibody comprises (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 294; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 295; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 296; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 297; (e) a FWL1 comprising an amino acid sequence of SEQ ID NO: 386; (f) a FWL2 comprising an amino acid sequence of SEQ ID NO: 387; (g) a FWL3 comprising an amino acid sequence of SEQ ID NO: 388; and (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 389. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to SEQ ID NO: 133; and a light chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to SEQ ID NO: 174. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 133; and a light chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 174. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 133; and a light chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 174. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 133; and a light chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 174. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region 57MF-363630230Attorney Docket No. 22419-20012.40comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 133; and a light chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 174. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 133; and a light chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 174. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to SEQ ID NO: 133; and a light chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to SEQ ID NO: 174. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according to SEQ ID NO: 133; and a light chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according SEQ ID NO: 174. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence according to SEQ ID NO: 133; and a light chain variable region comprising an amino acid sequence according to SEQ ID NO: 174. In some embodiments, the anti-DDRl antibody comprises a HC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 542; and a LC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 543. In some embodiments, the anti-DDRl antibody comprises an HC comprising an amino acid sequence according to SEQ ID NO: 542; and a LC comprising an amino acid sequence according to SEQ ID NO: 543. In some embodiments, the anti-DDRl antibody comprises an IgGl Fc domain comprising the amino acid modifications L234A / L235A (LALA), L234A / L235A / P329A (LALAPA), L234A / L235A / P329S (LALAPS), or L234A / L235A / P329G (LALAPG).

[0162] In some embodiments, the anti-DDRl antibody comprises a VH comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 134; and a VL comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%,58MF-363630230Attorney Docket No. 22419-20012.4096%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 175. In some embodiments, the anti-DDRl antibody comprises a VH comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 2, a CDR2 having an amino acid sequence according to SEQ ID NO: 25, and a CDR3 having an amino acid sequence according to SEQ ID NO: 48, and a VL comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 71, a CDR2 having an amino acid sequence according to SEQ ID NO: 92, and a CDR3 having an amino acid sequence according to SEQ ID NO: 113, and one or more FW region sequences selected from the group consisting of (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 298; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 299; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 300; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 301; (e) a FWL1 comprising an amino acid sequence of SEQ ID NO: 390; (f) a FWL2 comprising an amino acid sequence of SEQ ID NO: 391; (g) a FWL3 comprising an amino acid sequence of SEQ ID NO: 392; and / or (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 393. In some embodiments, the anti-DDRl antibody comprises (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 298; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 299; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 300; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 301; (e) a FWL1 comprising an amino acid sequence of SEQ ID NO: 390; (f) a FWL2 comprising an amino acid sequence of SEQ ID NO: 391; (g) a FWL3 comprising an amino acid sequence of SEQ ID NO: 392; and (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 393. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to SEQ ID NO: 134; and a light chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to SEQ ID NO: 175. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 134; and a light chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 175. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 134; and a light chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 175. In some embodiments,59MF-363630230Attorney Docket No. 22419-20012.40the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 134; and a light chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 175. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 134; and a light chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 175. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 134; and a light chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 175. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to SEQ ID NO: 134; and a light chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to SEQ ID NO: 175. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according to SEQ ID NO: 134; and a light chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according SEQ ID NO: 175. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence according to SEQ ID NO: 134; and a light chain variable region comprising an amino acid sequence according to SEQ ID NO: 175. In some embodiments, the anti-DDRl antibody comprises a HC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 216; and a LC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 217. In some embodiments, the anti-DDRl antibody comprises an HC comprising an amino acid sequence according to SEQ ID NO: 216; and a LC comprising an amino acid sequence according to SEQ ID NO: 217. In some embodiments, the anti-DDRl antibody comprises an IgGl Fc domain comprising the amino acid modifications60MF-363630230Attorney Docket No. 22419-20012.40L234A / L235A (LALA), L234A / L235A / P329A (LALAPA), L234A / L235A / P329S (LALAPS), or L234A / L235A / P329G (LALAPG).

[0163] In some embodiments, the anti-DDRl antibody comprises a VH comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 135; and a VL comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 176. In some embodiments, the anti-DDRl antibody comprises a VH comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 3, a CDR2 having an amino acid sequence according to SEQ ID NO: 26, and a CDR3 having an amino acid sequence according to SEQ ID NO: 49, and a VL comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 72, a CDR2 having an amino acid sequence according to SEQ ID NO: 93, and a CDR3 having an amino acid sequence according to SEQ ID NO: 114, and one or more FW region sequences selected from the group consisting of (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 302; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 303; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 304; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 305; (e) a FWL1 comprising an amino acid sequence of SEQ ID NO: 394; (f) a FWL2 comprising an amino acid sequence of SEQ ID NO: 395; (g) a FWL3 comprising an amino acid sequence of SEQ ID NO: 396; and / or (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 397. In some embodiments, the anti-DDRl antibody comprises (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 302; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 303; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 304; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 305; (e) a FWL1 comprising an amino acid sequence of SEQ ID NO: 394; (f) a FWL2 comprising an amino acid sequence of SEQ ID NO: 395; (g) a FWL3 comprising an amino acid sequence of SEQ ID NO: 396; and (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 397. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to SEQ ID NO: 135; and a light chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to SEQ ID NO: 176. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 135; and a light chain variable region comprising an 61MF-363630230Attorney Docket No. 22419-20012.40amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 176. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 135; and a light chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 176. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 135; and a light chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 176. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 135; and a light chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 176. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 135; and a light chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 176. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to SEQ ID NO: 135; and a light chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to SEQ ID NO: 176. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according to SEQ ID NO: 135; and a light chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according SEQ ID NO: 176. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence according to SEQ ID NO: 135; and a light chain variable region comprising an amino acid sequence according to SEQ ID NO: 176. In some embodiments, the anti-DDRl antibody comprises a HC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 218; and a LC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%,62MF-363630230Attorney Docket No. 22419-20012.4096%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 219. In some embodiments, the anti-DDRl antibody comprises an HC comprising an amino acid sequence according to SEQ ID NO: 218; and a LC comprising an amino acid sequence according to SEQ ID NO: 219. In some embodiments, the anti-DDRl antibody comprises an IgGl Fc domain comprising the amino acid modifications L234A / L235A (LALA), L234A / L235A / P329A (LALAPA), L234A / L235A / P329S (LALAPS), or L234A / L235A / P329G (LALAPG).

[0164] In some embodiments, the anti-DDRl antibody comprises a VH comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 136; and a VL comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 177. In some embodiments, the anti-DDRl antibody comprises a VH comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 4, a CDR2 having an amino acid sequence according to SEQ ID NO: 27, and a CDR3 having an amino acid sequence according to SEQ ID NO: 50, and a VL comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 73, a CDR2 having an amino acid sequence according to SEQ ID NO: 94, and a CDR3 having an amino acid sequence according to SEQ ID NO: 115, and one or more FW region sequences selected from the group consisting of (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 306; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 307; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 308; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 309; (e) a FWL1 comprising an amino acid sequence of SEQ ID NO: 398; (f) a FWL2 comprising an amino acid sequence of SEQ ID NO: 399; (g) a FWL3 comprising an amino acid sequence of SEQ ID NO: 400; and / or (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 401. In some embodiments, the anti-DDRl antibody comprises (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 306; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 307; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 308; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 309; (e) a FWL1 comprising an amino acid sequence of SEQ ID NO: 398; (f) a FWL2 comprising an amino acid sequence of SEQ ID NO: 399; (g) a FWL3 comprising an amino acid sequence of SEQ ID NO: 400; and (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 401. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to 63MF-363630230Attorney Docket No. 22419-20012.40SEQ ID NO: 136; and a light chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to SEQ ID NO: 177. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 136; and a light chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 177. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 136; and a light chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 177. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 136; and a light chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 177. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 136; and a light chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 177. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 136; and a light chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 177. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to SEQ ID NO: 136; and a light chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to SEQ ID NO: 177. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according to SEQ ID NO: 136; and a light chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according SEQ ID NO: 177. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence according to SEQ ID NO:64MF-363630230Attorney Docket No. 22419-20012.40136; and a light chain variable region comprising an amino acid sequence according to SEQ ID NO: 177. In some embodiments, the anti-DDRl antibody comprises a HC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 220; and a LC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 221. In some embodiments, the anti-DDRl antibody comprises an HC comprising an amino acid sequence according to SEQ ID NO: 220; and a LC comprising an amino acid sequence according to SEQ ID NO: 221. In some embodiments, the anti-DDRl antibody comprises an IgGl Fc domain comprising the amino acid modifications L234A / L235A (LALA), L234A / L235A / P329A (LALAPA), L234A / L235A / P329S (LALAPS), or L234A / L235A / P329G (LALAPG).

[0165] In some embodiments, the anti-DDRl antibody comprises a VH comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 137; and a VL comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 178. In some embodiments, the anti-DDRl antibody comprises a VH comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 5, a CDR2 having an amino acid sequence according to SEQ ID NO: 28, and a CDR3 having an amino acid sequence according to SEQ ID NO: 51, and a VL comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 74, a CDR2 having an amino acid sequence according to SEQ ID NO: 95, and a CDR3 having an amino acid sequence according to SEQ ID NO: 116, and one or more FW region sequences selected from the group consisting of (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 310; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 311; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 312; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 313; (e) a FWL1 comprising an amino acid sequence of SEQ ID NO: 402; (f) a FWL2 comprising an amino acid sequence of SEQ ID NO: 403; (g) a FWL3 comprising an amino acid sequence of SEQ ID NO: 404; and / or (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 405. In some embodiments, the anti-DDRl antibody comprises (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 310; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 311; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 312; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 313; (e) a FWL1 comprising an 65MF-363630230Attorney Docket No. 22419-20012.40amino acid sequence of SEQ ID NO: 402; (f) a FWL2 comprising an amino acid sequence of SEQ ID NO: 403; (g) a FWL3 comprising an amino acid sequence of SEQ ID NO: 404; and (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 405. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to SEQ ID NO: 137; and a light chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to SEQ ID NO: 178. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 137; and a light chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 178. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 137; and a light chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 178. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 137; and a light chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 178. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 137; and a light chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 178. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 137; and a light chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 178. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to SEQ ID NO: 137; and a light chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to SEQ ID NO: 178. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region 66MF-363630230Attorney Docket No. 22419-20012.40comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according to SEQ ID NO: 137; and a light chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according SEQ ID NO: 178. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence according to SEQ ID NO: 137; and a light chain variable region comprising an amino acid sequence according to SEQ ID NO: 178. In some embodiments, the anti-DDRl antibody comprises a HC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 222; and a LC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 223. In some embodiments, the anti-DDRl antibody comprises an HC comprising an amino acid sequence according to SEQ ID NO: 222; and a LC comprising an amino acid sequence according to SEQ ID NO: 223. In some embodiments, the anti-DDRl antibody comprises an IgGl Fc domain comprising the amino acid modifications L234A / L235A (LALA), L234A / L235A / P329A (LALAPA), L234A / L235A / P329S (LALAPS), or L234A / L235A / P329G (LALAPG).

[0166] In some embodiments, the anti-DDRl antibody comprises a VH comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 138; and a VL comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 179. In some embodiments, the anti-DDRl antibody comprises a VH comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 6, a CDR2 having an amino acid sequence according to SEQ ID NO: 29, and a CDR3 having an amino acid sequence according to SEQ ID NO: 52, and a VL comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 75, a CDR2 having an amino acid sequence according to SEQ ID NO: 96, and a CDR3 having an amino acid sequence according to SEQ ID NO: 117, and one or more FW region sequences selected from the group consisting of (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 314; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 315; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 316; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 317; (e) a FWL1 comprising an amino acid sequence of SEQ ID NO: 406; (f) a FWL2 comprising an amino acid sequence of SEQ ID NO: 407; (g) a FWL3 comprising an amino acid sequence of 67MF-363630230Attorney Docket No. 22419-20012.40SEQ ID NO: 408; and / or (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 409. In some embodiments, the anti-DDRl antibody comprises (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 314; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 315; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 316; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 317; (e) a FWL1 comprising an amino acid sequence of SEQ ID NO: 406; (f) a FWL2 comprising an amino acid sequence of SEQ ID NO: 407; (g) a FWL3 comprising an amino acid sequence of SEQ ID NO: 408; and (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 409. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to SEQ ID NO: 138; and a light chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to SEQ ID NO: 179. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 138; and a light chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 179. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 138; and a light chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 179. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 138; and a light chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 179. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 138; and a light chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 179. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 138; and a light chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 179. In some embodiments,68MF-363630230Attorney Docket No. 22419-20012.40the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to SEQ ID NO: 138; and a light chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to SEQ ID NO: 179. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according to SEQ ID NO: 138; and a light chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according SEQ ID NO: 179. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence according to SEQ ID NO: 138; and a light chain variable region comprising an amino acid sequence according to SEQ ID NO: 179. In some embodiments, the anti-DDRl antibody comprises a HC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 224; and a LC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 225. In some embodiments, the anti-DDRl antibody comprises an HC comprising an amino acid sequence according to SEQ ID NO: 224; and a LC comprising an amino acid sequence according to SEQ ID NO: 225. In some embodiments, the anti-DDRl antibody comprises an IgGl Fc domain comprising the amino acid modifications L234A / L235A (LALA), L234A / L235A / P329A (LALAPA), L234A / L235A / P329S (LALAPS), or L234A / L235A / P329G (LALAPG).

[0167] In some embodiments, the anti-DDRl antibody comprises a VH comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 139; and a VL comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 180. In some embodiments, the anti-DDRl antibody comprises a VH comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 7, a CDR2 having an amino acid sequence according to SEQ ID NO: 30, and a CDR3 having an amino acid sequence according to SEQ ID NO: 53, and a VL comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 76, a CDR2 having an amino acid sequence according to SEQ ID NO: 97, and a CDR3 having an amino acid sequence according to SEQ ID NO: 118, and one or more FW region sequences selected from the group consisting of (a)69MF-363630230Attorney Docket No. 22419-20012.40a FWH1 comprising an amino acid sequence of SEQ ID NO: 318; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 319; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 320; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 321; (e) a FWL1 comprising an amino acid sequence of SEQ ID NO: 410; (f) a FWL2 comprising an amino acid sequence of SEQ ID NO: 411; (g) a FWL3 comprising an amino acid sequence of SEQ ID NO: 412; and / or (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 413. In some embodiments, the anti-DDRl antibody comprises (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 318; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 319; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 320; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 321; (e) a FWL1 comprising an amino acid sequence of SEQ ID NO: 410; (f) a FWL2 comprising an amino acid sequence of SEQ ID NO: 411; (g) a FWL3 comprising an amino acid sequence of SEQ ID NO: 412; and (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 413. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to SEQ ID NO: 139; and a light chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to SEQ ID NO: 180. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 139; and a light chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 180. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 139; and a light chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 180. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 139; and a light chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 180. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 139; and a light chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence 70MF-363630230Attorney Docket No. 22419-20012.40according to SEQ ID NO: 180. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 139; and a light chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 180. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to SEQ ID NO: 139; and a light chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to SEQ ID NO: 180. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according to SEQ ID NO: 139; and a light chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according SEQ ID NO: 180. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence according to SEQ ID NO: 139; and a light chain variable region comprising an amino acid sequence according to SEQ ID NO: 180. In some embodiments, the anti-DDRl antibody comprises a HC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 226; and a LC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 227. In some embodiments, the anti-DDRl antibody comprises an HC comprising an amino acid sequence according to SEQ ID NO: 226; and a LC comprising an amino acid sequence according to SEQ ID NO: 227. In some embodiments, the anti-DDRl antibody comprises an IgGl Fc domain comprising the amino acid modifications L234A / L235A (LALA), L234A / L235A / P329A (LALAPA), L234A / L235A / P329S (LALAPS), or L234A / L235A / P329G (LALAPG).

[0168] In some embodiments, the anti-DDRl antibody comprises a VH comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 140; and a VL comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 181. In some embodiments, the anti-DDRl antibody comprises a VH comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 8, a CDR271MF-363630230Attorney Docket No. 22419-20012.40having an amino acid sequence according to SEQ ID NO: 31, and a CDR3 having an amino acid sequence according to SEQ ID NO: 54, and a VL comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 77, a CDR2 having an amino acid sequence according to SEQ ID NO: 98, and a CDR3 having an amino acid sequence according to SEQ ID NO: 119, and one or more FW region sequences selected from the group consisting of (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 322; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 323; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 324; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 325; (e) a FWL1 comprising an amino acid sequence of SEQ ID NO: 414; (f) a FWL2 comprising an amino acid sequence of SEQ ID NO: 415; (g) a FWL3 comprising an amino acid sequence of SEQ ID NO: 416; and / or (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 417. In some embodiments, the anti-DDRl antibody comprises (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 322; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 323; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 324; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 325; (e) a FWL1 comprising an amino acid sequence of SEQ ID NO: 414; (f) a FWL2 comprising an amino acid sequence of SEQ ID NO: 415; (g) a FWL3 comprising an amino acid sequence of SEQ ID NO: 416; and (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 417. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to SEQ ID NO: 140; and a light chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to SEQ ID NO: 181. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 140; and a light chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 181. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 140; and a light chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 181. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 140; and a light chain variable region comprising an amino acid sequence 72MF-363630230Attorney Docket No. 22419-20012.40having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 181. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 140; and a light chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 181. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 140; and a light chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 181. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to SEQ ID NO: 140; and a light chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to SEQ ID NO: 181. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according to SEQ ID NO: 140; and a light chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according SEQ ID NO: 181. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence according to SEQ ID NO: 140; and a light chain variable region comprising an amino acid sequence according to SEQ ID NO: 181. In some embodiments, the anti-DDRl antibody comprises a HC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 228; and a LC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 229. In some embodiments, the anti-DDRl antibody comprises an HC comprising an amino acid sequence according to SEQ ID NO: 228; and a LC comprising an amino acid sequence according to SEQ ID NO: 229. In some embodiments, the anti-DDRl antibody comprises an IgGl Fc domain comprising the amino acid modifications L234A / L235A (LALA), L234A / L235A / P329A (LALAPA), L234A / L235A / P329S (LALAPS), or L234A / L235A / P329G (LALAPG).

[0169] In some embodiments, the anti-DDRl antibody comprises a VH comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%,73MF-363630230Attorney Docket No. 22419-20012.40or more) sequence identity with an amino acid sequence according to SEQ ID NO: 141. In some embodiments, the anti-DDRl antibody comprises a VH comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 9, a CDR2 having an amino acid sequence according to SEQ ID NO: 32, and a CDR3 having an amino acid sequence according to SEQ ID NO: 55, and a VL comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 78, a CDR2 having an amino acid sequence according to SEQ ID NO: 99, and a CDR3 having an amino acid sequence according to SEQ ID NO: 120, and one or more FW region sequences selected from the group consisting of (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 326; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 327; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 328; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 329. In some embodiments, the anti-DDRl antibody comprises (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 326; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 327; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 328; and (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 329. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to SEQ ID NO: 141. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 141. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 141. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 141. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 141. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 141. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to SEQ ID NO: 141. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence 74MF-363630230Attorney Docket No. 22419-20012.40according to SEQ ID NO: 141. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence according to SEQ ID NO: 141. In some embodiments, the anti-DDRl antibody comprises a HC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 230. In some embodiments, the anti-DDRl antibody comprises an HC comprising an amino acid sequence according to SEQ ID NO: 230. In some embodiments, the anti-DDRl antibody comprises an IgGl Fc domain comprising the amino acid modifications L234A / L235A (LALA), L234A / L235A / P329A (LALAPA), L234A / L235A / P329S (LALAPS), or L234A / L235A / P329G (LALAPG).

[0170] In some embodiments, the anti-DDRl antibody comprises a VH comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 142; and a VL comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 182. In some embodiments, the anti-DDRl antibody comprises a VH comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 10, a CDR2 having an amino acid sequence according to SEQ ID NO: 33, and a CDR3 having an amino acid sequence according to SEQ ID NO: 56, and a VL comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 79, a CDR2 having an amino acid sequence according to SEQ ID NO: 100, and a CDR3 having an amino acid sequence according to SEQ ID NO: 121, and one or more FW region sequences selected from the group consisting of (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 330; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 331; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 332; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 333; (e) a FWL1 comprising an amino acid sequence of SEQ ID NO: 418; (f) a FWL2 comprising an amino acid sequence of SEQ ID NO: 419; (g) a FWL3 comprising an amino acid sequence of SEQ ID NO: 420; and / or (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 421. In some embodiments, the anti-DDRl antibody comprises (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 330; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 331; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 332; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 333; (e) a FWL1 comprising an amino acid sequence of SEQ ID NO: 418; (f) a FWL2 comprising an amino acid sequence of SEQ ID NO: 419; (g) a FWL3 comprising an amino acid sequence of 75MF-363630230Attorney Docket No. 22419-20012.40SEQ ID NO: 420; and (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 421. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to SEQ ID NO: 142; and a light chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to SEQ ID NO: 182. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 142; and a light chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 182. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 142; and a light chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 182. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 142; and a light chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 182. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 142; and a light chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 182. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 142; and a light chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 182. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to SEQ ID NO: 142; and a light chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to SEQ ID NO: 182. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according to SEQ ID NO: 142; and a light 76MF-363630230Attorney Docket No. 22419-20012.40chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according SEQ ID NO: 182. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence according to SEQ ID NO: 142; and a light chain variable region comprising an amino acid sequence according to SEQ ID NO: 182. In some embodiments, the anti-DDRl antibody comprises a HC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 231; and a LC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 232. In some embodiments, the anti-DDRl antibody comprises an HC comprising an amino acid sequence according to SEQ ID NO: 231; and a LC comprising an amino acid sequence according to SEQ ID NO: 232. In some embodiments, the anti-DDRl antibody comprises an IgGl Fc domain comprising the amino acid modifications L234A / L235A (LALA), L234A / L235A / P329A (LALAPA), L234A / L235A / P329S (LALAPS), or L234A / L235A / P329G (LALAPG).

[0171] In some embodiments, the anti-DDRl antibody comprises a VH comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 143; and a VL comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 183. In some embodiments, the anti-DDRl antibody comprises a VH comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 11, a CDR2 having an amino acid sequence according to SEQ ID NO: 34, and a CDR3 having an amino acid sequence according to SEQ ID NO: 57, and a VL comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 80, a CDR2 having an amino acid sequence according to SEQ ID NO: 101, and a CDR3 having an amino acid sequence according to SEQ ID NO: 122, and one or more FW region sequences selected from the group consisting of (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 334; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 335; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 336; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 337; (e) a FWL1 comprising an amino acid sequence of SEQ ID NO: 422; (f) a FWL2 comprising an amino acid sequence of SEQ ID NO: 423; (g) a FWL3 comprising an amino acid sequence of SEQ ID NO: 424; and / or (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 425. In some embodiments, the anti-DDRl antibody comprises (a)77MF-363630230Attorney Docket No. 22419-20012.40a FWH1 comprising an amino acid sequence of SEQ ID NO: 334; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 335; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 336; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 337; (e) a FWL1 comprising an amino acid sequence of SEQ ID NO: 422; (f) a FWL2 comprising an amino acid sequence of SEQ ID NO: 423; (g) a FWL3 comprising an amino acid sequence of SEQ ID NO: 424; and (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 425. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to SEQ ID NO: 143; and a light chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to SEQ ID NO: 183. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 140; and a light chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 183. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 143; and a light chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 183. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 143; and a light chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 183. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 143; and a light chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 183. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 143; and a light chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 183. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid 78MF-363630230Attorney Docket No. 22419-20012.40sequence according to SEQ ID NO: 143; and a light chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to SEQ ID NO: 183. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according to SEQ ID NO: 143; and a light chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according SEQ ID NO: 183. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence according to SEQ ID NO: 143; and a light chain variable region comprising an amino acid sequence according to SEQ ID NO: 183. In some embodiments, the anti-DDRl antibody comprises a HC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 233; and a LC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 234. In some embodiments, the anti-DDRl antibody comprises an HC comprising an amino acid sequence according to SEQ ID NO: 233; and a LC comprising an amino acid sequence according to SEQ ID NO: 234. In some embodiments, the anti-DDRl antibody comprises an IgGl Fc domain comprising the amino acid modifications L234A / L235A (LALA), L234A / L235A / P329A (LALAPA), L234A / L235A / P329S (LALAPS), or L234A / L235A / P329G (LALAPG).

[0172] In some embodiments, the anti-DDRl antibody comprises a VH comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 144; and a VL comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 184. In some embodiments, the anti-DDRl antibody comprises a VH comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 12, a CDR2 having an amino acid sequence according to SEQ ID NO: 35, and a CDR3 having an amino acid sequence according to SEQ ID NO: 58, and a VL comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 81, a CDR2 having an amino acid sequence according to SEQ ID NO: 102, and a CDR3 having an amino acid sequence according to SEQ ID NO: 123, and one or more FW region sequences selected from the group consisting of (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 338; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 339; (c) a FWH3 comprising an amino 79MF-363630230Attorney Docket No. 22419-20012.40acid sequence of SEQ ID NO: 340; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 341; (e) a FWL1 comprising an amino acid sequence of SEQ ID NO: 426; (f) a FWL2 comprising an amino acid sequence of SEQ ID NO: 427; (g) a FWL3 comprising an amino acid sequence of SEQ ID NO: 428; and / or (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 429. In some embodiments, the anti-DDRl antibody comprises (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 338; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 339; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 340; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 341; (e) a FWL1 comprising an amino acid sequence of SEQ ID NO: 426; (f) a FWL2 comprising an amino acid sequence of SEQ ID NO: 427; (g) a FWL3 comprising an amino acid sequence of SEQ ID NO: 428; and (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 429. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to SEQ ID NO: 144; and a light chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to SEQ ID NO: 184. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 144; and a light chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 184. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 144; and a light chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 184. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 144; and a light chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 184. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 144; and a light chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 184. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid 80MF-363630230Attorney Docket No. 22419-20012.40sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 144; and a light chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 184. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to SEQ ID NO: 144; and a light chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to SEQ ID NO: 184. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according to SEQ ID NO: 144; and a light chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according SEQ ID NO: 184. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence according to SEQ ID NO: 144; and a light chain variable region comprising an amino acid sequence according to SEQ ID NO: 184. In some embodiments, the anti-DDRl antibody comprises a HC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 235; and a LC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 236. In some embodiments, the anti-DDRl antibody comprises an HC comprising an amino acid sequence according to SEQ ID NO: 235; and a LC comprising an amino acid sequence according to SEQ ID NO: 236. In some embodiments, the anti-DDRl antibody comprises an IgGl Fc domain comprising the amino acid modifications L234A / L235A (LALA), L234A / L235A / P329A (LALAPA), L234A / L235A / P329S (LALAPS), or L234A / L235A / P329G (LALAPG).

[0173] In some embodiments, the anti-DDRl antibody comprises a VH comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 145. In some embodiments, the anti-DDRl antibody comprises a VH comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 13, a CDR2 having an amino acid sequence according to SEQ ID NO: 36, and a CDR3 having an amino acid sequence according to SEQ ID NO: 59, and one or more FW region sequences selected from the group consisting of (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 342; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 343; (c) a FWH3 comprising an amino acid sequence of 81MF-363630230Attorney Docket No. 22419-20012.40SEQ ID NO: 344; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 345. In some embodiments, the anti-DDRl antibody comprises (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 342; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 343; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 344; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 345. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to SEQ ID NO: 145. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 145. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 145. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 145. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 145. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 145. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to SEQ ID NO: 145. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according to SEQ ID NO: 145. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence according to SEQ ID NO: 145. In some embodiments, the anti-DDRl antibody comprises a HC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 237. In some embodiments, the anti-DDRl antibody comprises an HC comprising an amino acid sequence according to SEQ ID NO: 237. In some embodiments, the anti-DDRl antibody comprises an IgGl Fc domain comprising the amino acid modifications L234A / L235A (LALA), L234A / L235A / P329A (LALAPA), L234A / L235A / P329S (LALAPS), or L234A / L235A / P329G (LALAPG).82MF-363630230Attorney Docket No. 22419-20012.40

[0174] In some embodiments, the anti-DDRl antibody comprises a VH comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 146; and a VL comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 185. In some embodiments, the anti-DDRl antibody comprises a VH comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 14, a CDR2 having an amino acid sequence according to SEQ ID NO: 37, and a CDR3 having an amino acid sequence according to SEQ ID NO: 60, and a VL comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 213, a CDR2 having an amino acid sequence according to SEQ ID NO: 214, and a CDR3 having an amino acid sequence according to SEQ ID NO: 215, and one or more FW region sequences selected from the group consisting of (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 346; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 347; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 348; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 349; (e) a FWL1 comprising an amino acid sequence of SEQ ID NO: 430; (f) a FWL2 comprising an amino acid sequence of SEQ ID NO: 431; (g) a FWL3 comprising an amino acid sequence of SEQ ID NO: 432; and / or (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 433. In some embodiments, the anti-DDRl antibody comprises (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 346; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 347; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 348; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 349; (e) a FWL1 comprising an amino acid sequence of SEQ ID NO: 430; (f) a FWL2 comprising an amino acid sequence of SEQ ID NO: 431; (g) a FWL3 comprising an amino acid sequence of SEQ ID NO: 432; and (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 433. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to SEQ ID NO: 146; and a light chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to SEQ ID NO: 185. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 146; and a light chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 185. In some embodiments,83MF-363630230Attorney Docket No. 22419-20012.40the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 146; and a light chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 185. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 146; and a light chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 185. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 146; and a light chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 185. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 146; and a light chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 185. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to SEQ ID NO: 146; and a light chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to SEQ ID NO: 185. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according to SEQ ID NO: 146; and a light chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according SEQ ID NO: 185. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence according to SEQ ID NO: 146; and a light chain variable region comprising an amino acid sequence according to SEQ ID NO: 185. In some embodiments, the anti-DDRl antibody comprises a HC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 238; and a LC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 239. In some embodiments,84MF-363630230Attorney Docket No. 22419-20012.40the anti-DDRl antibody comprises an HC comprising an amino acid sequence according to SEQ ID NO: 238; and a LC comprising an amino acid sequence according to SEQ ID NO: 239. In some embodiments, the anti-DDRl antibody comprises an IgGl Fc domain comprising the amino acid modifications L234A / L235A (LALA), L234A / L235A / P329A (LALAPA), L234A / L235A / P329S (LALAPS), or L234A / L235A / P329G (LALAPG).

[0175] In some embodiments, the anti-DDRl antibody comprises a VH comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 147; and a VL comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 186. In some embodiments, the anti-DDRl antibody comprises a VH comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 15, a CDR2 having an amino acid sequence according to SEQ ID NO: 38, and a CDR3 having an amino acid sequence according to SEQ ID NO: 61, and a VL comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 82, a CDR2 having an amino acid sequence according to SEQ ID NO: 103, and a CDR3 having an amino acid sequence according to SEQ ID NO: 124, and one or more FW region sequences selected from the group consisting of (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 350; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 351; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 352; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 353; (e) a FWL1 comprising an amino acid sequence of SEQ ID NO: 434; (f) a FWL2 comprising an amino acid sequence of SEQ ID NO: 435; (g) a FWL3 comprising an amino acid sequence of SEQ ID NO: 436; and / or (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 437. In some embodiments, the anti-DDRl antibody comprises (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 350; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 351; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 352; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 353; (e) a FWL1 comprising an amino acid sequence of SEQ ID NO: 434; (f) a FWL2 comprising an amino acid sequence of SEQ ID NO: 435; (g) a FWL3 comprising an amino acid sequence of SEQ ID NO: 436; and (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 437. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to SEQ ID NO: 147; and a light chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence 85MF-363630230Attorney Docket No. 22419-20012.40according to SEQ ID NO: 186. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 147; and a light chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 186. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 147; and a light chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 186. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 147; and a light chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 186. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 147; and a light chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 186. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 147; and a light chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 186. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to SEQ ID NO: 147; and a light chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to SEQ ID NO: 186. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according to SEQ ID NO: 147; and a light chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according SEQ ID NO: 186. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence according to SEQ ID NO: 147; and a light chain variable region comprising an amino acid sequence according to SEQ ID NO: 186. In some embodiments, the anti-DDRl 86MF-363630230Attorney Docket No. 22419-20012.40antibody comprises a HC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 240; and a LC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 241. In some embodiments, the anti-DDRl antibody comprises an HC comprising an amino acid sequence according to SEQ ID NO: 240; and a LC comprising an amino acid sequence according to SEQ ID NO: 241. In some embodiments, the anti-DDRl antibody comprises an IgGl Fc domain comprising the amino acid modifications L234A / L235A (LALA), L234A / L235A / P329A (LALAPA), L234A / L235A / P329S (LALAPS), or L234A / L235A / P329G (LALAPG).

[0176] In some embodiments, the anti-DDRl antibody comprises a VH comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 148; and a VL comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 187. In some embodiments, the anti-DDRl antibody comprises a VH comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 15, a CDR2 having an amino acid sequence according to SEQ ID NO: 38, and a CDR3 having an amino acid sequence according to SEQ ID NO: 61, and a VL comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 83, a CDR2 having an amino acid sequence according to SEQ ID NO: 104, and a CDR3 having an amino acid sequence according to SEQ ID NO: 125, and one or more FW region sequences selected from the group consisting of (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 350; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 351; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 352; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 353; (e) a FWL1 comprising an amino acid sequence of SEQ ID NO: 438; (f) a FWL2 comprising an amino acid sequence of SEQ ID NO: 439; (g) a FWL3 comprising an amino acid sequence of SEQ ID NO: 440; and / or (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 441. In some embodiments, the anti-DDRl antibody comprises (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 350; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 351; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 352; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 353; (e) a FWL1 comprising an amino acid sequence of SEQ ID NO: 438; (f) a FWL2 comprising an amino acid sequence of SEQ ID NO: 439; (g) a FWL3 comprising an amino acid sequence of 87MF-363630230Attorney Docket No. 22419-20012.40SEQ ID NO: 440; and (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 441. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to SEQ ID NO: 148; and a light chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to SEQ ID NO: 187. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 148; and a light chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 187. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 148; and a light chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 187. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 148; and a light chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 187. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 148; and a light chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 187. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 148; and a light chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 187. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to SEQ ID NO: 148; and a light chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to SEQ ID NO: 187. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according to SEQ ID NO: 148; and a light 88MF-363630230Attorney Docket No. 22419-20012.40chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according SEQ ID NO: 187. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence according to SEQ ID NO: 148; and a light chain variable region comprising an amino acid sequence according to SEQ ID NO: 187. In some embodiments, the anti-DDRl antibody comprises a HC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 242; and a LC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 243. In some embodiments, the anti-DDRl antibody comprises an HC comprising an amino acid sequence according to SEQ ID NO: 242; and a LC comprising an amino acid sequence according to SEQ ID NO: 243. In some embodiments, the anti-DDRl antibody comprises an IgGl Fc domain comprising the amino acid modifications L234A / L235A (LALA), L234A / L235A / P329A (LALAPA), L234A / L235A / P329S (LALAPS), or L234A / L235A / P329G (LALAPG).

[0177] In some embodiments, the anti-DDRl antibody comprises a VH comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 149; and a VL comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 188. In some embodiments, the anti-DDRl antibody comprises a VH comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 15, a CDR2 having an amino acid sequence according to SEQ ID NO: 38, and a CDR3 having an amino acid sequence according to SEQ ID NO: 61, and a VL comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 84, a CDR2 having an amino acid sequence according to SEQ ID NO: 105, and a CDR3 having an amino acid sequence according to SEQ ID NO: 126, and one or more FW region sequences selected from the group consisting of (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 350; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 351; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 352; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 353; (e) a FWL1 comprising an amino acid sequence of SEQ ID NO: 442; (f) a FWL2 comprising an amino acid sequence of SEQ ID NO: 443; (g) a FWL3 comprising an amino acid sequence of SEQ ID NO: 444; and / or (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 445. In some embodiments, the anti-DDRl antibody comprises (a)89MF-363630230Attorney Docket No. 22419-20012.40a FWH1 comprising an amino acid sequence of SEQ ID NO: 350; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 351; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 352; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 353; (e) a FWL1 comprising an amino acid sequence of SEQ ID NO: 442; (f) a FWL2 comprising an amino acid sequence of SEQ ID NO: 443; (g) a FWL3 comprising an amino acid sequence of SEQ ID NO: 444; and (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 445. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to SEQ ID NO: 149; and a light chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to SEQ ID NO: 188. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 149; and a light chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 188. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 149; and a light chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 188. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 149; and a light chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 188. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 149; and a light chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 188. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 149; and a light chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 188. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid 90MF-363630230Attorney Docket No. 22419-20012.40sequence according to SEQ ID NO: 149; and a light chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to SEQ ID NO: 188. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according to SEQ ID NO: 149; and a light chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according SEQ ID NO: 188. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence according to SEQ ID NO: 149; and a light chain variable region comprising an amino acid sequence according to SEQ ID NO: 188. In some embodiments, the anti-DDRl antibody comprises a HC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 244; and a LC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 245. In some embodiments, the anti-DDRl antibody comprises an HC comprising an amino acid sequence according to SEQ ID NO: 244; and a LC comprising an amino acid sequence according to SEQ ID NO: 245. In some embodiments, the anti-DDRl antibody comprises an IgGl Fc domain comprising the amino acid modifications L234A / L235A (LALA), L234A / L235A / P329A (LALAPA), L234A / L235A / P329S (LALAPS), or L234A / L235A / P329G (LALAPG).

[0178] In some embodiments, the anti-DDRl antibody comprises a VH comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 150; and a VL comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 189. In some embodiments, the anti-DDRl antibody comprises a VH comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 16, a CDR2 having an amino acid sequence according to SEQ ID NO: 39, and a CDR3 having an amino acid sequence according to SEQ ID NO: 62, and a VL comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 82, a CDR2 having an amino acid sequence according to SEQ ID NO: 103, and a CDR3 having an amino acid sequence according to SEQ ID NO: 124, and one or more FW region sequences selected from the group consisting of (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 354; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 355; (c) a FWH3 comprising an amino 91MF-363630230Attorney Docket No. 22419-20012.40acid sequence of SEQ ID NO: 356; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 357; (e) a FWL1 comprising an amino acid sequence of SEQ ID NO: 446; (f) a FWL2 comprising an amino acid sequence of SEQ ID NO: 447; (g) a FWL3 comprising an amino acid sequence of SEQ ID NO: 448; and / or (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 449. In some embodiments, the anti-DDRl antibody comprises (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 354; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 355; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 356; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 357; (e) a FWL1 comprising an amino acid sequence of SEQ ID NO: 446; (f) a FWL2 comprising an amino acid sequence of SEQ ID NO: 447; (g) a FWL3 comprising an amino acid sequence of SEQ ID NO: 448; and (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 449. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to SEQ ID NO: 150; and a light chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to SEQ ID NO: 189. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 150; and a light chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 189. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 150; and a light chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 189. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 150; and a light chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 189. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 150; and a light chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 189. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid 92MF-363630230Attorney Docket No. 22419-20012.40sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 150; and a light chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 189. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to SEQ ID NO: 150; and a light chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to SEQ ID NO: 189. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according to SEQ ID NO: 150; and a light chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according SEQ ID NO: 189. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence according to SEQ ID NO: 150; and a light chain variable region comprising an amino acid sequence according to SEQ ID NO: 189. In some embodiments, the anti-DDRl antibody comprises a HC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 246; and a LC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 247. In some embodiments, the anti-DDRl antibody comprises an HC comprising an amino acid sequence according to SEQ ID NO: 246; and a LC comprising an amino acid sequence according to SEQ ID NO: 247. In some embodiments, the anti-DDRl antibody comprises an IgGl Fc domain comprising the amino acid modifications L234A / L235A (LALA), L234A / L235A / P329A (LALAPA), L234A / L235A / P329S (LALAPS), or L234A / L235A / P329G (LALAPG).

[0179] In some embodiments, the anti-DDRl antibody comprises a VH comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 151; and a VL comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 190. In some embodiments, the anti-DDRl antibody comprises a VH comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 16, a CDR2 having an amino acid sequence according to SEQ ID NO: 39, and a CDR3 having an amino acid sequence according to SEQ ID NO: 62, and a VL comprising a CDR1 having an amino 93MF-363630230Attorney Docket No. 22419-20012.40acid sequence according to SEQ ID NO: 83, a CDR2 having an amino acid sequence according to SEQ ID NO: 104, and a CDR3 having an amino acid sequence according to SEQ ID NO: 125, and one or more FW region sequences selected from the group consisting of (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 354; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 355; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 356; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 357; (e) a FWL1 comprising an amino acid sequence of SEQ ID NO: 450; (f) a FWL2 comprising an amino acid sequence of SEQ ID NO: 451; (g) a FWL3 comprising an amino acid sequence of SEQ ID NO: 452; and / or (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 453. In some embodiments, the anti-DDRl antibody comprises (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 354; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 355; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 356; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 357; (e) a FWL1 comprising an amino acid sequence of SEQ ID NO: 450; (f) a FWL2 comprising an amino acid sequence of SEQ ID NO: 451; (g) a FWL3 comprising an amino acid sequence of SEQ ID NO: 452; and (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 453. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to SEQ ID NO: 151; and a light chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to SEQ ID NO: 190. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 151; and a light chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 190. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 151; and a light chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 190. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 151; and a light chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 190. In some embodiments, the anti-DDRl antibody comprises a 94MF-363630230Attorney Docket No. 22419-20012.40heavy chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 151; and a light chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 190. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 151; and a light chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 190. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to SEQ ID NO: 151; and a light chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to SEQ ID NO: 190. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according to SEQ ID NO: 151; and a light chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according SEQ ID NO: 190. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence according to SEQ ID NO: 151; and a light chain variable region comprising an amino acid sequence according to SEQ ID NO: 190. In some embodiments, the anti-DDRl antibody comprises a HC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 248; and a LC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 249. In some embodiments, the anti-DDRl antibody comprises an HC comprising an amino acid sequence according to SEQ ID NO: 248; and a LC comprising an amino acid sequence according to SEQ ID NO: 249. In some embodiments, the anti-DDRl antibody comprises an IgGl Fc domain comprising the amino acid modifications L234A / L235A (LALA), L234A / L235A / P329A (LALAPA), L234A / L235A / P329S (LALAPS), or L234A / L235A / P329G (LALAPG).

[0180] In some embodiments, the anti-DDRl antibody comprises a VH comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 152; and a VL comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%,95MF-363630230Attorney Docket No. 22419-20012.4096%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 191. In some embodiments, the anti-DDRl antibody comprises a VH comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 16, a CDR2 having an amino acid sequence according to SEQ ID NO: 39, and a CDR3 having an amino acid sequence according to SEQ ID NO: 62, and a VL comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 84, a CDR2 having an amino acid sequence according to SEQ ID NO: 105, and a CDR3 having an amino acid sequence according to SEQ ID NO: 126, and one or more FW region sequences selected from the group consisting of (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 354; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 355; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 356; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 357; (e) a FWL1 comprising an amino acid sequence of SEQ ID NO: 454; (f) a FWL2 comprising an amino acid sequence of SEQ ID NO: 455; (g) a FWL3 comprising an amino acid sequence of SEQ ID NO: 456; and / or (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 457. In some embodiments, the anti-DDRl antibody comprises (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 354; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 355; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 356; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 357; (e) a FWL1 comprising an amino acid sequence of SEQ ID NO: 454; (f) a FWL2 comprising an amino acid sequence of SEQ ID NO: 455; (g) a FWL3 comprising an amino acid sequence of SEQ ID NO: 456; and (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 457. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to SEQ ID NO: 152; and a light chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to SEQ ID NO: 191. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 152; and a light chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 191. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 152; and a light chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO:96MF-363630230Attorney Docket No. 22419-20012.40191. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 152; and a light chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 191. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 152; and a light chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 191. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 152; and a light chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 191. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to SEQ ID NO: 152; and a light chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to SEQ ID NO: 191. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according to SEQ ID NO: 152; and a light chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according SEQ ID NO: 191. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence according to SEQ ID NO: 152; and a light chain variable region comprising an amino acid sequence according to SEQ ID NO: 191. In some embodiments, the anti-DDRl antibody comprises a HC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 250; and a LC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 251. In some embodiments, the anti-DDRl antibody comprises an HC comprising an amino acid sequence according to SEQ ID NO: 250; and a LC comprising an amino acid sequence according to SEQ ID NO: 251. In some embodiments, the anti-DDRl antibody comprises an IgGl Fc domain97MF-363630230Attorney Docket No. 22419-20012.40comprising the amino acid modifications L234A / L235A (LALA), L234A / L235A / P329A (LALAPA), L234A / L235A / P329S (LALAPS), or L234A / L235A / P329G (LALAPG).

[0181] In some embodiments, the anti-DDRl antibody comprises a VH comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 153; and a VL comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 192. In some embodiments, the anti-DDRl antibody comprises a VH comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 17, a CDR2 having an amino acid sequence according to SEQ ID NO: 40, and a CDR3 having an amino acid sequence according to SEQ ID NO: 63, and a VL comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 82, a CDR2 having an amino acid sequence according to SEQ ID NO: 103, and a CDR3 having an amino acid sequence according to SEQ ID NO: 124, and one or more FW region sequences selected from the group consisting of (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 358; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 359; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 360; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 361; (e) a FWL1 comprising an amino acid sequence of SEQ ID NO: 458; (f) a FWL2 comprising an amino acid sequence of SEQ ID NO: 459; (g) a FWL3 comprising an amino acid sequence of SEQ ID NO: 460; and / or (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 461. In some embodiments, the anti-DDRl antibody comprises (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 358; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 359; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 360; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 361; (e) a FWL1 comprising an amino acid sequence of SEQ ID NO: 458; (f) a FWL2 comprising an amino acid sequence of SEQ ID NO: 459; (g) a FWL3 comprising an amino acid sequence of SEQ ID NO: 460; and (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 461. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to SEQ ID NO: 153; and a light chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to SEQ ID NO: 192. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 153; and a light 98MF-363630230Attorney Docket No. 22419-20012.40chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 192. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 153; and a light chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 192. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 153; and a light chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 192. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 153; and a light chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 192. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 153; and a light chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 192. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to SEQ ID NO: 153; and a light chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to SEQ ID NO: 192. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according to SEQ ID NO: 153; and a light chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according SEQ ID NO: 192. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence according to SEQ ID NO: 153; and a light chain variable region comprising an amino acid sequence according to SEQ ID NO: 192. In some embodiments, the anti-DDRl antibody comprises a HC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 252; and a LC comprising an amino acid sequence 99MF-363630230Attorney Docket No. 22419-20012.40having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 253. In some embodiments, the anti-DDRl antibody comprises an HC comprising an amino acid sequence according to SEQ ID NO: 252; and a LC comprising an amino acid sequence according to SEQ ID NO: 253. In some embodiments, the anti-DDRl antibody comprises an IgGl Fc domain comprising the amino acid modifications L234A / L235A (LALA), L234A / L235A / P329A (LALAPA), L234A / L235A / P329S (LALAPS), or L234A / L235A / P329G (LALAPG).

[0182] In some embodiments, the anti-DDRl antibody comprises a VH comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 154; and a VL comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 193. In some embodiments, the anti-DDRl antibody comprises a VH comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 17, a CDR2 having an amino acid sequence according to SEQ ID NO: 40, and a CDR3 having an amino acid sequence according to SEQ ID NO: 63, and a VL comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 83, a CDR2 having an amino acid sequence according to SEQ ID NO: 104, and a CDR3 having an amino acid sequence according to SEQ ID NO: 125, and one or more FW region sequences selected from the group consisting of (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 358; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 359; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 360; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 361; (e) a FWL1 comprising an amino acid sequence of SEQ ID NO: 462; (f) a FWL2 comprising an amino acid sequence of SEQ ID NO: 463; (g) a FWL3 comprising an amino acid sequence of SEQ ID NO: 464; and / or (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 465. In some embodiments, the anti-DDRl antibody comprises (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 358; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 359; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 360; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 361; (e) a FWL1 comprising an amino acid sequence of SEQ ID NO: 462; (f) a FWL2 comprising an amino acid sequence of SEQ ID NO: 463; (g) a FWL3 comprising an amino acid sequence of SEQ ID NO: 464; and (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 465. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid 100MF-363630230Attorney Docket No. 22419-20012.40sequence according to SEQ ID NO: 154; and a light chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to SEQ ID NO: 193. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 154; and a light chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 193. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 154; and a light chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 193. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 154; and a light chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 193. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 154; and a light chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 193. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 154; and a light chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 193. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to SEQ ID NO: 154; and a light chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to SEQ ID NO: 193. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according to SEQ ID NO: 154; and a light chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according SEQ ID NO: 193. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid 101MF-363630230Attorney Docket No. 22419-20012.40sequence according to SEQ ID NO: 154; and a light chain variable region comprising an amino acid sequence according to SEQ ID NO: 193. In some embodiments, the anti-DDRl antibody comprises a HC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 254; and a LC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 255. In some embodiments, the anti-DDRl antibody comprises an HC comprising an amino acid sequence according to SEQ ID NO: 254; and a LC comprising an amino acid sequence according to SEQ ID NO: 255. In some embodiments, the anti-DDRl antibody comprises an IgGl Fc domain comprising the amino acid modifications L234A / L235A (LALA), L234A / L235A / P329A (LALAPA), L234A / L235A / P329S (LALAPS), or L234A / L235A / P329G (LALAPG).

[0183] In some embodiments, the anti-DDRl antibody comprises a VH comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 155; and a VL comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 194. In some embodiments, the anti-DDRl antibody comprises a VH comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 17, a CDR2 having an amino acid sequence according to SEQ ID NO: 40, and a CDR3 having an amino acid sequence according to SEQ ID NO: 63, and a VL comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 84, a CDR2 having an amino acid sequence according to SEQ ID NO: 105, and a CDR3 having an amino acid sequence according to SEQ ID NO: 126, and one or more FW region sequences selected from the group consisting of (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 358; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 359; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 360; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 361; (e) a FWL1 comprising an amino acid sequence of SEQ ID NO: 466; (f) a FWL2 comprising an amino acid sequence of SEQ ID NO: 467; (g) a FWL3 comprising an amino acid sequence of SEQ ID NO: 468; and / or (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 469. In some embodiments, the anti-DDRl antibody comprises (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 358; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 359; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 360; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 361; (e) a 102MF-363630230Attorney Docket No. 22419-20012.40FWL1 comprising an amino acid sequence of SEQ ID NO: 466; (f) a FWL2 comprising an amino acid sequence of SEQ ID NO: 467; (g) a FWL3 comprising an amino acid sequence of SEQ ID NO: 468; and (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 469. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to SEQ ID NO: 155; and a light chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to SEQ ID NO: 194. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 155; and a light chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 194. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 155; and a light chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 194. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 155; and a light chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 194. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 155; and a light chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 194. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 155; and a light chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 194. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to SEQ ID NO: 155; and a light chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to SEQ ID NO: 194. In some embodiments, the anti-DDRl antibody comprises a 103MF-363630230Attorney Docket No. 22419-20012.40heavy chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according to SEQ ID NO: 155; and a light chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according SEQ ID NO: 194. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence according to SEQ ID NO: 155; and a light chain variable region comprising an amino acid sequence according to SEQ ID NO: 194. In some embodiments, the anti-DDRl antibody comprises a HC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 256; and a LC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 257. In some embodiments, the anti-DDRl antibody comprises an HC comprising an amino acid sequence according to SEQ ID NO: 256; and a LC comprising an amino acid sequence according to SEQ ID NO: 257. In some embodiments, the anti-DDRl antibody comprises an IgGl Fc domain comprising the amino acid modifications L234A / L235A (LALA), L234A / L235A / P329A (LALAPA), L234A / L235A / P329S (LALAPS), or L234A / L235A / P329G (LALAPG).

[0184] In some embodiments, the anti-DDRl antibody comprises a VH comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 156; and a VL comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 195. In some embodiments, the anti-DDRl antibody comprises a VH comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 18, a CDR2 having an amino acid sequence according to SEQ ID NO: 41, and a CDR3 having an amino acid sequence according to SEQ ID NO: 64, and a VL comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 85, a CDR2 having an amino acid sequence according to SEQ ID NO: 106, and a CDR3 having an amino acid sequence according to SEQ ID NO: 127, and one or more FW region sequences selected from the group consisting of (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 362; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 363; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 364; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 365; (e) a FWL1 comprising an amino acid sequence of SEQ ID NO: 470; (f) a FWL2 comprising an amino acid sequence of SEQ ID NO: 471; (g) a FWL3 comprising an 104MF-363630230Attorney Docket No. 22419-20012.40amino acid sequence of SEQ ID NO: 472; and / or (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 473. In some embodiments, the anti-DDRl antibody comprises (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 362; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 363; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 364; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 365; (e) a FWL1 comprising an amino acid sequence of SEQ ID NO: 470; (f) a FWL2 comprising an amino acid sequence of SEQ ID NO: 471; (g) a FWL3 comprising an amino acid sequence of SEQ ID NO: 472; and (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 473. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to SEQ ID NO: 156; and a light chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to SEQ ID NO: 195. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 156; and a light chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 195. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 156; and a light chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 195. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 156; and a light chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 195. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 156; and a light chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 195. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 156; and a light chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO:105MF-363630230Attorney Docket No. 22419-20012.40195. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to SEQ ID NO: 156; and a light chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to SEQ ID NO: 195. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according to SEQ ID NO: 156; and a light chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according SEQ ID NO: 195. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence according to SEQ ID NO: 156; and a light chain variable region comprising an amino acid sequence according to SEQ ID NO: 195. In some embodiments, the anti-DDRl antibody comprises a HC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 258; and a LC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 259. In some embodiments, the anti-DDRl antibody comprises an HC comprising an amino acid sequence according to SEQ ID NO: 258; and a LC comprising an amino acid sequence according to SEQ ID NO: 259. In some embodiments, the anti-DDRl antibody comprises an IgGl Fc domain comprising the amino acid modifications L234A / L235A (LALA), L234A / L235A / P329A (LALAPA), L234A / L235A / P329S (LALAPS), or L234A / L235A / P329G (LALAPG).

[0185] In some embodiments, the anti-DDRl antibody comprises a VH comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 157; and a VL comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 196. In some embodiments, the anti-DDRl antibody comprises a VH comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 18, a CDR2 having an amino acid sequence according to SEQ ID NO: 41, and a CDR3 having an amino acid sequence according to SEQ ID NO: 64, and a VL comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 86, a CDR2 having an amino acid sequence according to SEQ ID NO: 107, and a CDR3 having an amino acid sequence according to SEQ ID NO: 128, and one or more FW region sequences selected from the group consisting 106MF-363630230Attorney Docket No. 22419-20012.40of (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 362; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 363; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 364; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 365; (e) a FWL1 comprising an amino acid sequence of SEQ ID NO: 474; (f) a FWL2 comprising an amino acid sequence of SEQ ID NO: 475; (g) a FWL3 comprising an amino acid sequence of SEQ ID NO: 476; and / or (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 477. In some embodiments, the anti-DDRl antibody comprises (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 362; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 363; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 364; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 365; (e) a FWL1 comprising an amino acid sequence of SEQ ID NO: 474; (f) a FWL2 comprising an amino acid sequence of SEQ ID NO: 475; (g) a FWL3 comprising an amino acid sequence of SEQ ID NO: 476; and (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 477. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to SEQ ID NO: 157; and a light chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to SEQ ID NO: 196. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 157; and a light chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 196. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 157; and a light chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 196. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 157; and a light chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 196. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 157; and a light chain variable region comprising an amino acid sequence having at least 96% sequence 107MF-363630230Attorney Docket No. 22419-20012.40identity with an amino acid sequence according to SEQ ID NO: 196. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 157; and a light chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 196. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to SEQ ID NO: 157; and a light chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to SEQ ID NO: 196. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according to SEQ ID NO: 157; and a light chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according SEQ ID NO: 196. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence according to SEQ ID NO: 157; and a light chain variable region comprising an amino acid sequence according to SEQ ID NO: 196. In some embodiments, the anti-DDRl antibody comprises a HC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 260; and a LC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 261. In some embodiments, the anti-DDRl antibody comprises an HC comprising an amino acid sequence according to SEQ ID NO: 260; and a LC comprising an amino acid sequence according to SEQ ID NO: 261. In some embodiments, the anti-DDRl antibody comprises an IgGl Fc domain comprising the amino acid modifications L234A / L235A (LALA), L234A / L235A / P329A (LALAPA), L234A / L235A / P329S (LALAPS), or L234A / L235A / P329G (LALAPG).

[0186] In some embodiments, the anti-DDRl antibody comprises a VH comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 158; and a VL comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 197. In some embodiments, the anti-DDRl antibody comprises a VH comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 18, a CDR2108MF-363630230Attorney Docket No. 22419-20012.40having an amino acid sequence according to SEQ ID NO: 41, and a CDR3 having an amino acid sequence according to SEQ ID NO: 64, and a VL comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 87, a CDR2 having an amino acid sequence according to SEQ ID NO: 108, and a CDR3 having an amino acid sequence according to SEQ ID NO: 129, and one or more FW region sequences selected from the group consisting of (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 362; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 363; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 364; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 365; (e) a FWL1 comprising an amino acid sequence of SEQ ID NO: 478; (f) a FWL2 comprising an amino acid sequence of SEQ ID NO: 479; (g) a FWL3 comprising an amino acid sequence of SEQ ID NO: 480; and / or (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 481. In some embodiments, the anti-DDRl antibody comprises (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 362; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 363; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 364; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 365; (e) a FWL1 comprising an amino acid sequence of SEQ ID NO: 478; (f) a FWL2 comprising an amino acid sequence of SEQ ID NO: 479; (g) a FWL3 comprising an amino acid sequence of SEQ ID NO: 480; and (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 481. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to SEQ ID NO: 158; and a light chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to SEQ ID NO: 197. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 158; and a light chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 197. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 158; and a light chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 197. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 158; and a light chain variable region comprising an 109MF-363630230Attorney Docket No. 22419-20012.40amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 197. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 158; and a light chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 197. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 158; and a light chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 197. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to SEQ ID NO: 158; and a light chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to SEQ ID NO: 197. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according to SEQ ID NO: 158; and a light chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according SEQ ID NO: 197. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence according to SEQ ID NO: 158; and a light chain variable region comprising an amino acid sequence according to SEQ ID NO: 197. In some embodiments, the anti-DDRl antibody comprises a HC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 262; and a LC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 263. In some embodiments, the anti-DDRl antibody comprises an HC comprising an amino acid sequence according to SEQ ID NO: 262; and a LC comprising an amino acid sequence according to SEQ ID NO: 263. In some embodiments, the anti-DDRl antibody comprises an IgGl Fc domain comprising the amino acid modifications L234A / L235A (LALA), L234A / L235A / P329A (LALAPA), L234A / L235A / P329S (LALAPS), or L234A / L235A / P329G (LALAPG).

[0187] In some embodiments, the anti-DDRl antibody comprises a VH comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%,110MF-363630230Attorney Docket No. 22419-20012.40or more) sequence identity with an amino acid sequence according to SEQ ID NO: 159; and a VL comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 198. In some embodiments, the anti-DDRl antibody comprises a VH comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 19, a CDR2 having an amino acid sequence according to SEQ ID NO: 42, and a CDR3 having an amino acid sequence according to SEQ ID NO: 65, and a VL comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 85, a CDR2 having an amino acid sequence according to SEQ ID NO: 106, and a CDR3 having an amino acid sequence according to SEQ ID NO: 127, and one or more FW region sequences selected from the group consisting of (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 366; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 367; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 368; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 369; (e) a FWL1 comprising an amino acid sequence of SEQ ID NO: 482; (f) a FWL2 comprising an amino acid sequence of SEQ ID NO: 483; (g) a FWL3 comprising an amino acid sequence of SEQ ID NO: 484; and / or (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 485. In some embodiments, the anti-DDRl antibody comprises (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 366; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 367; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 368; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 369; (e) a FWL1 comprising an amino acid sequence of SEQ ID NO: 482; (f) a FWL2 comprising an amino acid sequence of SEQ ID NO: 483; (g) a FWL3 comprising an amino acid sequence of SEQ ID NO: 484; and (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 485. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to SEQ ID NO: 159; and a light chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to SEQ ID NO: 198. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 159; and a light chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 198. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to 111MF-363630230Attorney Docket No. 22419-20012.40SEQ ID NO: 159; and a light chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 198. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 159; and a light chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 198. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 159; and a light chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 198. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 159; and a light chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 198. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to SEQ ID NO: 159; and a light chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to SEQ ID NO: 198. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according to SEQ ID NO: 159; and a light chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according SEQ ID NO: 198. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence according to SEQ ID NO: 159; and a light chain variable region comprising an amino acid sequence according to SEQ ID NO: 198. In some embodiments, the anti-DDRl antibody comprises a HC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 264; and a LC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 265. In some embodiments, the anti-DDRl antibody comprises an HC comprising an amino acid sequence according to SEQ ID NO: 264; and a LC comprising an amino acid sequence according to SEQ ID NO:112MF-363630230Attorney Docket No. 22419-20012.40265. In some embodiments, the anti-DDRl antibody comprises an IgGl Fc domain comprising the amino acid modifications L234A / L235A (LALA), L234A / L235A / P329A (LALAPA), L234A / L235A / P329S (LALAPS), or L234A / L235A / P329G (LALAPG).

[0188] In some embodiments, the anti-DDRl antibody comprises a VH comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 160; and a VL comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 199. In some embodiments, the anti-DDRl antibody comprises a VH comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 19, a CDR2 having an amino acid sequence according to SEQ ID NO: 42, and a CDR3 having an amino acid sequence according to SEQ ID NO: 65, and a VL comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 86, a CDR2 having an amino acid sequence according to SEQ ID NO: 107, and a CDR3 having an amino acid sequence according to SEQ ID NO: 128, and one or more FW region sequences selected from the group consisting of (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 366; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 367; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 368; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 369; (e) a FWL1 comprising an amino acid sequence of SEQ ID NO: 486; (f) a FWL2 comprising an amino acid sequence of SEQ ID NO: 487; (g) a FWL3 comprising an amino acid sequence of SEQ ID NO: 488; and / or (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 489. In some embodiments, the anti-DDRl antibody comprises (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 366; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 367; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 368; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 369; (e) a FWL1 comprising an amino acid sequence of SEQ ID NO: 486; (f) a FWL2 comprising an amino acid sequence of SEQ ID NO: 487; (g) a FWL3 comprising an amino acid sequence of SEQ ID NO: 488; and (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 489. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to SEQ ID NO: 160; and a light chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to SEQ ID NO: 199. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 85%113MF-363630230Attorney Docket No. 22419-20012.40sequence identity with an amino acid sequence according to SEQ ID NO: 160; and a light chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 199. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 160; and a light chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 199. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 160; and a light chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 199. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 160; and a light chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 199. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 160; and a light chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 199. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to SEQ ID NO: 160; and a light chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to SEQ ID NO: 199. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according to SEQ ID NO: 160; and a light chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according SEQ ID NO: 199. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence according to SEQ ID NO: 160; and a light chain variable region comprising an amino acid sequence according to SEQ ID NO: 199. In some embodiments, the anti-DDRl antibody comprises a HC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid 114MF-363630230Attorney Docket No. 22419-20012.40sequence according to SEQ ID NO: 266; and a LC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 267. In some embodiments, the anti-DDRl antibody comprises an HC comprising an amino acid sequence according to SEQ ID NO: 266; and a LC comprising an amino acid sequence according to SEQ ID NO: 267. In some embodiments, the anti-DDRl antibody comprises an IgGl Fc domain comprising the amino acid modifications L234A / L235A (LALA), L234A / L235A / P329A (LALAPA), L234A / L235A / P329S (LALAPS), or L234A / L235A / P329G (LALAPG).

[0189] In some embodiments, the anti-DDRl antibody comprises a VH comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 161; and a VL comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 200. In some embodiments, the anti-DDRl antibody comprises a VH comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 19, a CDR2 having an amino acid sequence according to SEQ ID NO: 42, and a CDR3 having an amino acid sequence according to SEQ ID NO: 65, and a VL comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 87, a CDR2 having an amino acid sequence according to SEQ ID NO: 108, and a CDR3 having an amino acid sequence according to SEQ ID NO: 129, and one or more FW region sequences selected from the group consisting of (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 366; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 367; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 368; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 369; (e) a FWL1 comprising an amino acid sequence of SEQ ID NO: 490; (f) a FWL2 comprising an amino acid sequence of SEQ ID NO: 491; (g) a FWL3 comprising an amino acid sequence of SEQ ID NO: 492; and / or (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 493. In some embodiments, the anti-DDRl antibody comprises (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 366; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 367; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 368; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 369; (e) a FWL1 comprising an amino acid sequence of SEQ ID NO: 490; (f) a FWL2 comprising an amino acid sequence of SEQ ID NO: 491; (g) a FWL3 comprising an amino acid sequence of SEQ ID NO: 492; and (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 493. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region 115MF-363630230Attorney Docket No. 22419-20012.40comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to SEQ ID NO: 161; and a light chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to SEQ ID NO: 200. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 161; and a light chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 200. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 161; and a light chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 200. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 161; and a light chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 200. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 161; and a light chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 200. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 161; and a light chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 200. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to SEQ ID NO: 161; and a light chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to SEQ ID NO: 200. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according to SEQ ID NO: 161; and a light chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according SEQ ID NO: 200. In some embodiments, the 116MF-363630230Attorney Docket No. 22419-20012.40anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence according to SEQ ID NO: 161; and a light chain variable region comprising an amino acid sequence according to SEQ ID NO: 200. In some embodiments, the anti-DDRl antibody comprises a HC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 268; and a LC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 269. In some embodiments, the anti-DDRl antibody comprises an HC comprising an amino acid sequence according to SEQ ID NO: 268; and a LC comprising an amino acid sequence according to SEQ ID NO: 269. In some embodiments, the anti-DDRl antibody comprises an IgGl Fc domain comprising the amino acid modifications L234A / L235A (LALA), L234A / L235A / P329A (LALAPA), L234A / L235A / P329S (LALAPS), or L234A / L235A / P329G (LALAPG).

[0190] In some embodiments, the anti-DDRl antibody comprises a VH comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 162; and a VL comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 201. In some embodiments, the anti-DDRl antibody comprises a VH comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 20, a CDR2 having an amino acid sequence according to SEQ ID NO: 43, and a CDR3 having an amino acid sequence according to SEQ ID NO: 66, and a VL comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 85, a CDR2 having an amino acid sequence according to SEQ ID NO: 106, and a CDR3 having an amino acid sequence according to SEQ ID NO: 127, and one or more FW region sequences selected from the group consisting of (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 370; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 371; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 372; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 373; (e) a FWL1 comprising an amino acid sequence of SEQ ID NO: 494; (f) a FWL2 comprising an amino acid sequence of SEQ ID NO: 495; (g) a FWL3 comprising an amino acid sequence of SEQ ID NO: 496; and / or (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 497. In some embodiments, the anti-DDRl antibody comprises (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 370; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 371; (c) a FWH3 comprising an amino acid sequence of 117MF-363630230Attorney Docket No. 22419-20012.40SEQ ID NO: 372; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 373; (e) a FWL1 comprising an amino acid sequence of SEQ ID NO: 494; (f) a FWL2 comprising an amino acid sequence of SEQ ID NO: 495; (g) a FWL3 comprising an amino acid sequence of SEQ ID NO: 496; and (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 497. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to SEQ ID NO: 162; and a light chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to SEQ ID NO: 201. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 162; and a light chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 201. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 162; and a light chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 201. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 162; and a light chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 201. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 162; and a light chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 201. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 162; and a light chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 201. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to SEQ ID NO: 162; and a light chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence 118MF-363630230Attorney Docket No. 22419-20012.40according to SEQ ID NO: 201. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according to SEQ ID NO: 162; and a light chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according SEQ ID NO: 201. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence according to SEQ ID NO: 162; and a light chain variable region comprising an amino acid sequence according to SEQ ID NO: 201. In some embodiments, the anti-DDRl antibody comprises a HC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 270; and a LC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 271. In some embodiments, the anti-DDRl antibody comprises an HC comprising an amino acid sequence according to SEQ ID NO: 270; and a LC comprising an amino acid sequence according to SEQ ID NO: 271. In some embodiments, the anti-DDRl antibody comprises an IgGl Fc domain comprising the amino acid modifications L234A / L235A (LALA), L234A / L235A / P329A (LALAPA), L234A / L235A / P329S (LALAPS), or L234A / L235A / P329G (LALAPG).

[0191] In some embodiments, the anti-DDRl antibody comprises a VH comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 163; and a VL comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 202. In some embodiments, the anti-DDRl antibody comprises a VH comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 20, a CDR2 having an amino acid sequence according to SEQ ID NO: 43, and a CDR3 having an amino acid sequence according to SEQ ID NO: 66, and a VL comprising a CDR1 having an amino acid sequence according to SEQ ID NO: 86, a CDR2 having an amino acid sequence according to SEQ ID NO: 107, and a CDR3 having an amino acid sequence according to SEQ ID NO: 128, and one or more FW region sequences selected from the group consisting of (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 370; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 371; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 372; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 373; (e) a FWL1 comprising an amino acid sequence of SEQ ID NO: 498; (f) a 119MF-363630230Attorney Docket No. 22419-20012.40FWL2 comprising an amino acid sequence of SEQ ID NO: 499; (g) a FWL3 comprising an amino acid sequence of SEQ ID NO: 500; and / or (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 501. In some embodiments, the anti-DDRl antibody comprises (a) a FWH1 comprising an amino acid sequence of SEQ ID NO: 370; (b) a FWH2 comprising an amino acid sequence of SEQ ID NO: 371; (c) a FWH3 comprising an amino acid sequence of SEQ ID NO: 372; (d) a FWH4 comprising an amino acid sequence of SEQ ID NO: 373; (e) a FWL1 comprising an amino acid sequence of SEQ ID NO: 498; (f) a FWL2 comprising an amino acid sequence of SEQ ID NO: 499; (g) a FWL3 comprising an amino acid sequence of SEQ ID NO: 500; and (h) a FWL4 comprising an amino acid sequence of SEQ ID NO: 501. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to SEQ ID NO: 163; and a light chain variable region comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence according to SEQ ID NO: 202. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 163; and a light chain variable region comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence according to SEQ ID NO: 202. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 163; and a light chain variable region comprising an amino acid sequence having at least 90% sequence identity with an amino acid sequence according to SEQ ID NO: 202. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 163; and a light chain variable region comprising an amino acid sequence having at least 95% sequence identity with an amino acid sequence according to SEQ ID NO: 202. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 163; and a light chain variable region comprising an amino acid sequence having at least 96% sequence identity with an amino acid sequence according to SEQ ID NO: 202. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 163; and a light chain variable region comprising an amino acid sequence 120MF-363630230Attorney Docket No. 22419-20012.40having at least 97% sequence identity with an amino acid sequence according to SEQ ID NO: 202. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to SEQ ID NO: 163; and a light chain variable region comprising an amino acid sequence having at least 98% sequence identity with an amino acid sequence according to SEQ ID NO: 202. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according to SEQ ID NO: 163; and a light chain variable region comprising an amino acid sequence having at least 99% sequence identity with an amino acid sequence according SEQ ID NO: 202. In some embodiments, the anti-DDRl antibody comprises a heavy chain variable region comprising an amino acid sequence according to SEQ ID NO: 163; and a light chain variable region comprising an amino acid sequence according to SEQ ID NO: 202. In some embodiments, the anti-DDRl antibody comprises a HC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 272; and a LC comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 273. In some embodiments, the anti-DDRl antibody comprises an HC comprising an amino acid sequence according to SEQ ID NO: 272; and a LC comprising an amino acid sequence according to SEQ ID NO: 273. In some embodiments, the anti-DDRl antibody comprises an IgGl Fc domain comprising the amino acid modifications L234A / L235A (LALA), L234A / L235A / P329A (LALAPA), L234A / L235A / P329S (LALAPS), or L234A / L235A / P329G (LALAPG).

[0192] In some embodiments, the anti-DDRl antibody comprises a VH comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 164; and a VL comprising an amino acid sequence having at least about 80% (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with an amino acid sequence according to SEQ ID NO: 203. In som...

Claims

Attorney Docket No. 22419-20012.40CLAIMS1. An antibody or an antigen-binding fragment thereof that binds Discoidin Domain Receptor 1 (DDR1), comprising:a) a heavy chain variable region (VH) comprising at least about 90% sequence identity to any one of SEQ ID NOs: 153-155 and 171-173, at least about 91% sequence identity to any of SEQ ID NOs: 165-167, at least about 94% sequence identity to any one of SEQ ID NOs: 147-149 and 156-158, at least about 95% sequence identity to any one of SEQ ID NOs: 162-164, or at least about 97% sequence identity to any one of SEQ ID NOs: 150-152, 159-161, and 168-170; and b) a light chain variable region (VL) comprising at least about 95% sequence identity to any one of SEQ ID NOs: 195, 198, 201, 205, 206, 207, 209, 210, and 212, at least about 96% sequence identity to any one of SEQ ID NOs: 197, 200, and 203, at least about 97% sequence identity to any one of SEQ ID NOs: 187, 190, 193, 196, 199, and 202, at least about 98% sequence identity to any one of SEQ ID NOs: 188, 191, 194, 205, 208, and 211, or an amino acid sequence according to any one of SEQ ID NOs: 186, 189, and 192.

2. An antibody or an antigen-binding fragment thereof that binds Discoidin Domain Receptor 1 (DDR1), comprising:a) a heavy chain variable region (VH) comprising (i) a complementarity determining region (CDR) 1 having an amino acid sequence according to any one of SEQ ID NOs: 1-23; (ii) a CDR2 having an amino acid sequence according to any one of SEQ ID NOs: 24-46; and (iii) a CDR3 having an amino acid sequence according to any one of SEQ ID NOs: 47-69; andb) a light chain variable region (VL) comprising (i) a complementarity determining region (CDR) 1 having an amino acid sequence according to any one of SEQ ID NOs: 70-90; (ii) a CDR2 having an amino acid sequence according to any one of SEQ ID NOs: 91-111; and (iii) a CDR3 having an amino acid sequence according to any one of SEQ ID NOs: 112-132.

3. An immunoconjugate comprising:a) an antibody or antigen-binding fragment that binds to Discoidin Domain Receptor 1 (DDR1), wherein the antibody or antigen-binding fragment thereof comprises:274MF-363630230Attorney Docket No. 22419-20012.40a heavy chain variable region (VH) comprising (i) a complementarity determining region (CDR) 1 having an amino acid sequence according to any one of SEQ ID NOs: 1-23; (ii) a CDR2 having an amino acid sequence according to any one of SEQ ID NOs: 24-46; and (iii) a CDR3 having an amino acid sequence according to any one of SEQ ID NOs: 47-69; anda light chain variable region (VL) comprising (i) a CDR1 having an amino acid sequence according to any one of SEQ ID NOs: 70-90; (ii) a CDR2 having an amino acid sequence according to any one of SEQ ID NOs: 91-111; and (iii) a CDR3 having an amino acid sequence according to any one of SEQ ID NOs: 112-132; and b) a topoisomerase I inhibitor conjugated to the antibody or the antigen-binding fragment thereof using a linker.

4. The immunoconjugate of claim 3, wherein the topoisomerase I inhibitor is represented by Formula (II) having the structure:R- X3—(II)wherein:R1and R2are each individually selected from the group consisting of hydrogen, halogen, -CN, -OR5, -NR5R6, a substituted or an unsubstituted Ci-Ce alkyl, a substituted or unsubstituted Ci-Cehaloalkyl, a substituted or unsubstituted -O-(Ci-Ce alkyl), a substituted or unsubstituted -O-(Ci-Ce haloalkyl), and - [(CY2)pO(CY2)q]tCY3, or a substituted or unsubstituted -O-(CR5R6)m-O- such that R1and R2are taken together form a ring;275MF-363630230Attorney Docket No. 22419-20012.40R3is a hydrogen or a substituted or an unsubstituted Ci-Ce alkyl, a substituted or an unsubstituted Ci-Ce haloalkyl, or — [(CY2)pO(CY2)q]tCY3;R4is hydrogen, a substituted or an unsubstituted — (Ci-Ce alkyl)-X2, a substituted or an unsubstituted — (Ci-Ce haloalkyl)-X2, a substituted or an unsubstituted — (Ci-Ce alkenyl)-X2, a substituted or an unsubstituted — (Ci-C6haloalkenyl)-X2, a substituted or an unsubstituted — (Ci-Ce alkynyl)-X2, or a substituted or an unsubstituted — (Ci-Ce haloalkynyl)-X2;X1is — O—, — S(O)W—, — NH—, — O— (C=O)—, — NH— (C=O)—, — NH— (C=O)— O—, — NH— (C=O)— NH—, or — NH— S(O)W—;X2is —OR9, —SR9, or — NHR9;R5and R6are each individually hydrogen, halogen, a substituted or an unsubstituted Ci-Ce alkyl, a substituted or an unsubstituted Ci-Ce haloalkyl, or — [(CY2)pO(CY2)q]tCY3;m is 1 or 2;n4and n5are each individually 0, 1 or 2, with the proviso that n4and n5are not both 0; each w is 0, 1 or 2;each Y is individually hydrogen or halogen;each p is individually 1, 2, 3, 4, 5, or 6;each q is individually 0, 1, 2, 3, 4, 5, or 6;each t is individually 1, 2, 3, 4, 5, or 6;R7is hydrogen, — COR8, — CO2R8, — (CO) — NHR8, or the point of attachment to the linker;R8is a substituted or an unsubstituted Ci-Ce alkyl-X3, a substituted or an unsubstituted Ci-Ce haloalkyl-X3, or — [(CY2)PO(CY2)q]tCY2 — X3;R9is hydrogen, — COR8, — CO2R8, — (CO) — NHR8, or the point of attachment to the linker, with the proviso that exactly one of R7and R9is the point of attachment to the linker; andeach X3is individually — H, — OH, — SH, or — NH2.276MF-363630230Attorney Docket No. 22419-20012.

405. The immunoconjugate of claim 4, wherein the topoisomerase I inhibitor is represented by Formula (II) having the structure:(II)wherein:R1and R2are each individually selected from the group consisting of hydrogen, halogen, -OR5, unsubstituted Ci-Ce alkyl, unsubstituted Ci-Ce haloalkyl and unsubstituted -O-(Ci-Ce alkyl), or unsubstituted -O-(CR5R6)m-O- such that R1and R2are taken together form a ring;R3is hydrogen or unsubstituted Ci-Ce alkyl;R4is a substituted or unsubstituted — (Ci-Ce alkyl)-X2;X1is — O—;X2is —OR9;R5and R6are each individually hydrogen;m is 1;n4is 1 or 2;n5is 0;R7is hydrogen; andR9is the point of attachment to the linker.

6. The immunoconjugate of claim 4 or 5, wherein n4is 1.277MF-363630230Attorney Docket No. 22419-20012.

407. The immunoconjugate of claim 4 or 5, wherein n4is 2.

8. The immunoconjugate of claim 4 or 5, wherein the topoisomerase I inhibitor comprises Formula (II) having the structure:wherein:R1is methyl;R2is fluoro;R3is hydrogen;R4is a substituted or unsubstituted -(C2 alkyl)-X2; andn4is 2.

9. The immunoconjugate of claim 4 or 5, wherein the topoisomerase I inhibitor is represented by:wherein R9is the point of attachment to the linker.

10. The immunoconjugate of claim 4 or 5, wherein the topoisomerase I inhibitor is represented by:278MF-363630230Attorney Docket No. 22419-20012.40wherein R9is the point of attachment to the linker.

11. The immunoconjugate of claim 4 or 5, wherein the topoisomerase I inhibitor is represented by:wherein R9is the point of attachment to the linker.

12. The immunoconjugate of any one of claims 3-5, wherein the topoisomerase I inhibitor and the linker, taken together, are represented by:279MF-363630230Attorney Docket No. 22419-20012.4013. The immunoconjugate of any one of claims 3-5, wherein the topoisomerase I inhibitor and the linker, taken together, are represented by:

14. The immunoconjugate of any one of claims 3-5, wherein the topoisomerase I inhibitor and the linker, taken together, are represented by:280MF-363630230Attorney Docket No. 22419-20012.4015. The immunoconjugate of any one of claims 3-5, wherein the topoisomerase I inhibitor and the linker, taken together, are represented by:

16. The immunoconjugate of any one of claims 3-5, wherein the topoisomerase I inhibitor and the linker, taken together, are represented by:281MF-363630230Attorney Docket No. 22419-20012.4017. An immunoconjugate having Formula (I),Ab-[S-L1-L2-L3-L4-L5-L6-L7-D]n(I)wherein:Ab is an antibody or an antigen-binding fragment thereof that binds Discoidin Domain Receptor 1 (DDR1), comprising:a heavy chain variable region (VH) comprising (i) a complementarity determining region (CDR) 1 having an amino acid sequence according to any one of SEQ ID NOs: 1-23; (ii) a CDR2 having an amino acid sequence according to any one of SEQ ID NOs: 24-46; and (iii) a CDR3 having an amino acid sequence according to any one of SEQ ID NOs: 47-69; anda light chain variable region (VL) comprising (i) a CDR1 having an amino acid sequence according to any one of SEQ ID NOs: 70-90; (ii) a CDR2 having an amino acid sequence according to any one of SEQ ID NOs: 91-111; and (iii) a CDR3 having an amino acid sequence according to any one of SEQ ID NOs: 112-132; S is a sulfur atom of a cysteine of the antibody or the antigen-binding fragment thereof;L1is0 •L2is absent,282MF-363630230Attorney Docket No. 22419-20012.40Z1z1Z1and Z2are each individually hydrogen, halogen, NO2, -O-(Ci-Ce alkyl), or Ci-Ce alkyl;L3is -(CH2)n1-C(=O)- or -(CH2CH2O)n1-(CH2)n1C(=O)-;each n1is individually an integer from 0 to 10;L4is a tetrapeptide residue;L5is absent or -[NH(CH2)n2]n3- n2is an integer from 0 to 6;n3is an integer from 0 to 2;L6is absent,, wherein G is a beta- glucuronic acidL7is absent,D is a drug moiety; andn is an integer from 1 to 10.

18. The immunoconjugate of claim 17, wherein the drug moiety is represented by Formula (II) having the structure:283MF-363630230Attorney Docket No. 22419-20012.40(II)wherein:R1and R2are each individually selected from the group consisting of hydrogen, halogen, -CN, -OR5, -NR5R6, a substituted or an unsubstituted Ci-Ce alkyl, a substituted or unsubstituted Ci-Ce haloalkyl, a substituted or unsubstituted -O-(Ci-Ce alkyl), a substituted or unsubstituted -O-(Ci-Ce haloalkyl), and -[(CY2)pO(CY2)q]tCY3, or a substituted or unsubstituted -O-(CR5R6)m-O- such that R1and R2are taken together form a ring;R3is a hydrogen, a substituted or an unsubstituted Ci-Ce alkyl, a substituted or an unsubstituted Ci-Ce haloalkyl, or — [(CY2)PO(CY2)q]tCY3;R4is hydrogen, a substituted or an unsubstituted — (Ci-Ce alkyl)-X2, a substituted or an unsubstituted — (Ci-Ce haloalkyl)-X2, a substituted or an unsubstituted — (Ci-Ce alkenyl)-X2, a substituted or an unsubstituted — (Ci-C6haloalkenyl)-X2, a substituted or an unsubstituted — (Ci-Ce alkynyl)-X2, or a substituted or an unsubstituted — (Ci-Ce haloalkynyl)-X2;X1is — O—, — S(O)W—, — NH—, — O— (C=O)—, — NH— (C=O)—, — NH— (C=O)— O—, — NH— (C=O)— NH—, or — NH— S(O)W—;X2is —OR9, —SR9, or — NHR9;R5and R6are each individually hydrogen, halogen, a substituted or an unsubstituted Ci-Ce alkyl, a substituted or an unsubstituted Ci-Ce haloalkyl, or — [(CY2)pO(CY2)q]tCY3;m is 1 or 2;284MF-363630230Attorney Docket No. 22419-20012.40n4and n5are each individually 0, 1 or 2, with the proviso that n4and n5are not both 0; each w is 0, 1 or 2;each Y is individually hydrogen or halogen;each p is individually 1, 2, 3, 4, 5, or 6;each q is individually 0, 1, 2, 3, 4, 5, or 6;each t is individually 1, 2, 3, 4, 5, or 6;R7is H, —COR8, — CO2R8, — (CO)— NHR8, L4, L5, L6, or L7;R8is a substituted or an unsubstituted Ci-Ce alkyl-X3, a substituted or an unsubstituted Ci-Ce haloalkyl-X3, or — [(CY2)pO(CY2)q]tCY2 — X3;R9is hydrogen, — COR8, — CO2R8, — (CO) — NHR8, L4, L5, L6, or L7, with the proviso that exactly one of R7and R9is L4, L5, L6, or L7; andeach X3is individually — H, — OH, — SH, or — NH2.

19. The immunoconjugate of claim 18, wherein the drug moiety of Formula (II) is represented by:(II)wherein:R1and R2are each individually selected from the group consisting of hydrogen, halogen, -OR5, unsubstituted Ci-Ce alkyl, unsubstituted Ci-Ce haloalkyl, and unsubstituted -O-(Ci-Ce alkyl), or unsubstituted -O-(CR5R6)m-O- such that R1and R2are taken together form a ring;285MF-363630230Attorney Docket No. 22419-20012.40R3is a hydrogen or an unsubstituted Ci-Ce alkyl;R4is a substituted or an unsubstituted — (Ci-Ce alkyl)-X2;X1is — O—;X2is —OR9;R5and R6are each individually hydrogen;m is 1;n4is 1 or 2;n5is 0;R7is hydrogen; andR9is L4, L5, L6, or L7.

20. The immunoconjugate of claim 18 or 19, wherein n4is 1.

21. The immunoconjugate of claim 18 or 19, wherein n4is 2.

22. The immunoconjugate of claim 18 or 19, wherein the drug moiety of Formula (II) is represented by:wherein:R1is methyl;R2is fluoro;R3is hydrogen;R4is a substituted or an unsubstituted -(C2 alkyl)-X2; andn4is 2.286MF-363630230Attorney Docket No. 22419-20012.4023. The immunoconjugate of any one of claims 17-22, wherein:L2is absent;n1is the integer 2 or 5;L4is gly-gly-phe-gly;L5is -[NH(CH2)n2]n3-;n2is the integer 1;n3is the integer 1; andL7is absent.

24. The immunoconjugate of claim 18 or 19, wherein the drug moiety of Formula (II) is represented by:OR9wherein R9is L4, L5, L6, or L7.

25. The immunoconjugate of claim 18 or 19, wherein the drug moiety of Formula (II) is represented by:OR9wherein R9is L4, L5, L6, or L7.287MF-363630230Attorney Docket No. 22419-20012.4026. The immunoconjugate of claim 18 or 19, wherein the drug moiety of Formula (II) is represented by:

27. The immunoconjugate of any one of claims 17-19, wherein Formula (I) is represented by:

28. The immunoconjugate of any one of claims 17-19, wherein Formula (I) is represented by:288MF-363630230Attorney Docket No. 22419-20012.4029. The immunoconjugate of any one of claims 17-19, wherein Formula (I) is represented by:289MF-363630230Attorney Docket No. 22419-20012.4030. The immunoconjugate of any one of claims 17-19, wherein Formula (I) is represented by:

31. The immunoconjugate of any one of claims 17-19, wherein Formula (I) is represented by:290MF-363630230Attorney Docket No. 22419-20012.4032. An immunoconjugate having Formula (I),Ab-tS-L^-L’-L^-L^L’-D](I)wherein:Ab is an antibody or an antigen-binding fragment thereof that binds Discoidin Domain Receptor 1 (DDR1), comprising:a heavy chain variable region (VH) comprising (i) a complementarity determining region (CDR) 1 having an amino acid sequence according to any one of SEQ ID NOs: 1-23; (ii) a CDR2 having an amino acid sequence according to any one of SEQ ID NOs: 24-46; and (iii) a CDR3 having an amino acid sequence according to any one of SEQ ID NOs: 47-69; anda light chain variable region (VL) comprising (i) a CDR1 having an amino acid sequence according to any one of SEQ ID NOs: 70-90; (ii) a CDR2 having an amino acid sequence according to any one of SEQ ID NOs: 91-111; and (iii) a CDR3 having an amino acid sequence according to any one of SEQ ID NOs: 112-132;291MF-363630230Attorney Docket No. 22419-20012.40S is a sulfur atom of a cysteine of the antibody or the antigen-binding fragment thereof;L2is absent,Z1and Z2are each individually hydrogen, halogen, NO2, -O-(Ci-Ce alkyl), or Ci-Ce alkyl;L3is -(CH2)n1-C(=O)- or -(CH2CH2O)n1-(CH2)n1C(=O)-;each n1is individually an integer from 0 to 10;L4is a tetrapeptide residue;L5is absent or -[NH(CH2)n2]n3- n2is an integer from 0 to 6;n3is an integer from 0 to 2;L6is absent,H N O, or, wherein G is a beta- glucuronic acid moiety;L7is absent,292MF-363630230Attorney Docket No. 22419-20012.40n is an integer from 1 to 10.

33. The immunoconjugate of any one of claims 17-32, wherein n is an integer from 4 to 8.

34. The immunoconjugate of any one of claims 3-33, wherein the VH comprises an amino acid sequence having at least about 80% sequence identity to any one of SEQ ID NOs: 133-173.

35. The immunoconjugate of any one of claims 3-34, wherein the VL comprises an amino acid sequence having at least about 80% sequence identity to any one of SEQ ID NOs: 174-212.

36. The immunoconjugate of any one of claims 3-35, wherein the VH comprises an amino acid sequence having at least about 80% sequence identity to any one of SEQ ID NOs: 133-173 and the VL comprises an amino acid sequence having at least about 80% sequence identity to any one of SEQ ID NOs: 174-212.

37. The antibody or the antigen-binding fragment thereof of claim 1 or 2 or the immunoconjugate of any one of claims 3-36, wherein the VH comprises an amino acid sequence according to any one of SEQ ID NOs: 133-173.293MF-363630230Attorney Docket No. 22419-20012.4038. The antibody or the antibody fragment thereof of any one of claims 1, 2, and 37, or the immunoconjugate of any one of claims 3-37, wherein the VL comprises an amino acid sequence according to any one of SEQ ID NOs: 174-212.

39. The antibody or the antibody fragment thereof of any one of claims 1, 2, 37, and 38 or the immunoconjugate of any one of claims 3-38, wherein the VH comprises an amino acid sequence according to any one of SEQ ID NOs: 133-173 and the VL comprises an amino acid sequence according to any one of SEQ ID NOs: 174-212.

40. The antibody or the antibody fragment thereof of any one of claims claim 1, 2, and 37-39 or the immunoconjugate of any one of claims 3-39, wherein the antibody or the antigenbinding fragment thereof comprises:i) a VH comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 1, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 24, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 47; and a VL comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 70, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 91, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 112;ii) a VH comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 2, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 25, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 48; and a VL comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 71, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 92, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 113;iii) a VH comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 3, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 26, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 49; and a VL comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 72, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 93, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 114;294MF-363630230Attorney Docket No. 22419-20012.40iv) a VH comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 4, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 27, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 50; and a VL comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 73, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 94, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 115;v) a VH comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 5, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 28, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 51; and a VL comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 74, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 95, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 116;vi) a VH comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 6, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 29, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 52; and a VL comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 75, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 96, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 117;vii) a VH comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 7, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 30, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 53; and a VL comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 76, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 97, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 118;viii) a VH comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 8, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 31, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 54; and a VL comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 77, (ii) a CDR2 having an amino acid sequence according to SEQ ID295MF-363630230Attorney Docket No. 22419-20012.40NO: 98, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 119;ix) a VH comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 9, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 32, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 55; and a VL comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 78, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 99, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 120;x) a VH comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 10, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 33, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 56; and a VL comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 79, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 100, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 121;xi) a VH comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 11, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 34, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 57; and a VL comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 80, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 101, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 122;xii) a VH comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 12, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 35, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 58; and a VL comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 81, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 102, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 123;xiii) a VH comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 13, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 36, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 59;296MF-363630230Attorney Docket No. 22419-20012.40xiv) a VH comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 14, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 37, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 60; xv) a VH comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 15, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 38, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 61; and a VL comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 82, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 103, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 124;xvi) a VH comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 16, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 39, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 62; and a VL comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 83, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 104, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 125;xvii) a VH comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 17, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 40, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 63; and a VL comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 84, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 105, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 126;xviii) a VH comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 18, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 41, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 64; and a VL comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 85, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 106, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 127;xix) a VH comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 19, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 42, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 65;297MF-363630230Attorney Docket No. 22419-20012.40and a VL comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 86, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 107, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 128;xx) a VH comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 20, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 43, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 66; and a VL comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 87, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 108, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 129;xxi) a VH comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 21, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 44, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 67; and a VL comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 88, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 109, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 130;xxii) a VH comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 22, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 45, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 68; and a VL comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 89, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 110, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 131; orxxiii) a VH comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 23, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 46, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 69; and a VL comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 90, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 111, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 132.298MF-363630230Attorney Docket No. 22419-20012.4041. The antibody or the antibody fragment thereof of any one of claims 1, 2, and 37-40 or the immunoconjugate of any one of claims 3-40, wherein the antibody or the antigen-binding fragment thereof comprises:a) a VH comprising an amino acid sequence according to SEQ ID NO: 133, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 133, and a VL comprising an amino acid sequence according to SEQ ID NO: 174, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 174;b) a VH comprising an amino acid sequence according to SEQ ID NO: 134, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 134, and a VL comprising an amino acid sequence according to SEQ ID NO: 175, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 175;c) a VH comprising an amino acid sequence according to SEQ ID NO: 135, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 135, and a VL comprising an amino acid sequence according to SEQ ID NO: 176, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 176;d) a VH comprising an amino acid sequence according to SEQ ID NO: 136, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 136, and a VL comprising an amino acid sequence according to SEQ ID NO: 177, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 177;e) a VH comprising an amino acid sequence according to SEQ ID NO: 137, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 137, and a VL comprising an amino acid sequence according to SEQ ID NO: 178, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 178;f) a VH comprising an amino acid sequence according to SEQ ID NO: 138, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 138, and a VL comprising an amino acid sequence according to SEQ ID NO: 179, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 179;299MF-363630230Attorney Docket No. 22419-20012.40g) a VH comprising an amino acid sequence according to SEQ ID NO: 139, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 139, and a VL comprising an amino acid sequence according to SEQ ID NO: 180, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 180;h) a VH comprising an amino acid sequence according to SEQ ID NO: 140, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 140, and a VL comprising an amino acid sequence according to SEQ ID NO: 181, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 181;i) a VH comprising an amino acid sequence according to SEQ ID NO: 141, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 141; j) a VH comprising an amino acid sequence according to SEQ ID NO: 142, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 142, and a VL comprising an amino acid sequence according to SEQ ID NO: 182, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 182;k) a VH comprising an amino acid sequence according to SEQ ID NO: 143, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 143, and a VL comprising an amino acid sequence according to SEQ ID NO: 183, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 183;l) a VH comprising an amino acid sequence according to SEQ ID NO: 144, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 144, and a VL comprising an amino acid sequence according to SEQ ID NO: 184, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 184;m) a VH comprising an amino acid sequence according to SEQ ID NO: 145, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 145; n) a VH comprising an amino acid sequence according to SEQ ID NO: 146, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 146, and a VL comprising an amino acid sequence according to SEQ ID NO: 185, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 185;300MF-363630230Attorney Docket No. 22419-20012.40o) a VH comprising an amino acid sequence according to SEQ ID NO: 147, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 147, and a VL comprising an amino acid sequence according to SEQ ID NO: 186, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 186;p) a VH comprising an amino acid sequence according to SEQ ID NO: 148, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 148, and a VL comprising an amino acid sequence according to SEQ ID NO: 187, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 187;q) a VH comprising an amino acid sequence according to SEQ ID NO: 149, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 149, and a VL comprising an amino acid sequence according to SEQ ID NO: 188, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 188;r) a VH comprising an amino acid sequence according to SEQ ID NO: 150, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 150, and a VL comprising an amino acid sequence according to SEQ ID NO: 189, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 189;s) a VH comprising an amino acid sequence according to SEQ ID NO: 151, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 151, and a VL comprising an amino acid sequence according to SEQ ID NO: 190, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 190;t) a VH comprising an amino acid sequence according to SEQ ID NO: 152, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 152, and a VL comprising an amino acid sequence according to SEQ ID NO: 191, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 191;u) a VH comprising an amino acid sequence according to SEQ ID NO: 153, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 153, and a VL comprising an amino acid sequence according to SEQ ID NO: 192, or an301MF-363630230Attorney Docket No. 22419-20012.40amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 192;v) a VH comprising an amino acid sequence according to SEQ ID NO: 154, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 154, and a VL comprising an amino acid sequence according to SEQ ID NO: 193, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 193;w) a VH comprising an amino acid sequence according to SEQ ID NO: 155, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 155, and a VL comprising an amino acid sequence according to SEQ ID NO: 194, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 194;x) a VH comprising an amino acid sequence according to SEQ ID NO: 156, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 156, and a VL comprising an amino acid sequence according to SEQ ID NO: 195, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 195;y) a VH comprising an amino acid sequence according to SEQ ID NO: 157, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 157, and a VL comprising an amino acid sequence according to SEQ ID NO: 196, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 196;z) a VH comprising an amino acid sequence according to SEQ ID NO: 158, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 158, and a VL comprising an amino acid sequence according to SEQ ID NO: 197, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 197;aa) a VH comprising an amino acid sequence according to SEQ ID NO: 159, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 159, and a VL comprising an amino acid sequence according to SEQ ID NO: 198, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 198;bb) a VH comprising an amino acid sequence according to SEQ ID NO: 160, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 160,302MF-363630230Attorney Docket No. 22419-20012.40and a VL comprising an amino acid sequence according to SEQ ID NO: 199, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 199;cc) a VH comprising an amino acid sequence according to SEQ ID NO: 161, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 161, and a VL comprising an amino acid sequence according to SEQ ID NO: 200, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 200;dd) a VH comprising an amino acid sequence according to SEQ ID NO: 162, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 162, and a VL comprising an amino acid sequence according to SEQ ID NO: 201, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 201;ee) a VH comprising an amino acid sequence according to SEQ ID NO: 163, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 163, and a VL comprising an amino acid sequence according to SEQ ID NO: 202, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 202;ff) a VH comprising an amino acid sequence according to SEQ ID NO: 164, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 164, and a VL comprising an amino acid sequence according to SEQ ID NO: 203, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 203;gg) a VH comprising an amino acid sequence according to SEQ ID NO: 165, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 165, and a VL comprising an amino acid sequence according to SEQ ID NO: 204, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 204;hh) a VH comprising an amino acid sequence according to SEQ ID NO: 166, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 166, and a VL comprising an amino acid sequence according to SEQ ID NO: 205, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 205;303MF-363630230Attorney Docket No. 22419-20012.40ii) a VH comprising an amino acid sequence according to SEQ ID NO: 167, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 167, and a VL comprising an amino acid sequence according to SEQ ID NO: 206, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 206;jj) a VH comprising an amino acid sequence according to SEQ ID NO: 168, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 168, and a VL comprising an amino acid sequence according to SEQ ID NO: 207, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 207;kk) a VH comprising an amino acid sequence according to SEQ ID NO: 169, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 169, and a VL comprising an amino acid sequence according to SEQ ID NO: 208, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 208;ll) a VH comprising an amino acid sequence according to SEQ ID NO: 170, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 170, and a VL comprising an amino acid sequence according to SEQ ID NO: 209, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 209;mm) a VH comprising an amino acid sequence according to SEQ ID NO: 171, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 171, and a VL comprising an amino acid sequence according to SEQ ID NO: 210, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 210;nn) a VH comprising an amino acid sequence according to SEQ ID NO: 172, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 172, and a VL comprising an amino acid sequence according to SEQ ID NO: 211, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 211; oroo) a VH comprising an amino acid sequence according to SEQ ID NO: 173, or an amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 173, and a VL comprising an amino acid sequence according to SEQ ID NO: 212, or an304MF-363630230Attorney Docket No. 22419-20012.40amino acid sequence comprising at least about 80% sequence identity to SEQ ID NO: 212.

42. The antibody or the antigen-binding fragment thereof of any one of claims 1, 2, and 38-41 or the immunoconjugate of any one of claims 3-41, wherein the antibody comprises a Fc domain comprising one or more modifications that reduces binding to an Fc receptor, reduces binding to complement component Clq, or reduces binding to an Fc receptor and reduces binding to complement component Clq.

43. The antibody or the antigen-binding fragment thereof or the immunoconjugate of claim 42, wherein the antibody comprises a Fc domain comprising the amino acid modifications E234A / E235A (EAEA), E234A / E235A / P329A (EAEAPA), E234A / E235A / P329G (EAEAPG), E234A / E235A / P329S (EAEAPS).

44. The antibody or the antigen-binding fragment thereof of any one of claims 1, 2, and 37-43 or the immunoconjugate of any one of claims 3-43, wherein the antibody or the antigenbinding fragment thereof binds to human DDR1 with an affinity of 10’6M to 1010M.

45. An immunoconjugate having Formula (I),Ab-[S-E1-E2-E3-E4-E5-E6-E7-D]n(I)wherein:Ab is an antibody or an antigen-binding fragment thereof that binds Discoidin Domain Receptor 1 (DDR1), comprising:a heavy chain variable region (VH) comprising the amino acid sequence according to SEQ ID NO: 164; anda light chain variable region (VL) comprising the amino acid sequence according to SEQ ID NO: 203;S is a sulfur atom of a cysteine of the antibody or the antigen-binding fragment thereof;305MF-363630230Attorney Docket No. 22419-20012.40L2is absent;L3is -(CH2)n1-C(=O)-;n1is the integer 2 or 5;L4is gly-gly-phe-gly;L5is -[NH(CH2)n2]n3-;n2is the integer 1;n3is the integer 1;L6is absent;L7is absent;D has the structure:

46. An immunoconjugate having Formula (I),Ab-tS-L^-L’-L^-L^-DK(I)wherein:Ab is an antibody or an antigen-binding fragment thereof that binds Discoidin Domain Receptor 1 (DDR1), comprising:a heavy chain variable region (VH) comprising the amino acid sequence according to SEQ ID NO: 153; anda light chain variable region (VL) comprising the amino acid sequence according to SEQ ID NO: 192;S is a sulfur atom of a cysteine of the antibody or the antigen-binding fragment thereof;306MF-363630230Attorney Docket No. 22419-20012.40L1is O;L2is absent;L3is -(CH2)n1-C(=O)-;n1is the integer 2 or 5;L4is gly-gly-phe-gly;L5is -[NH(CH2)n2]n3-;n2is the integer 1;n3is the integer 1;L6is absent;L7is absent;D has the structure:

47. The immunoconjugate of claim 45 or 46, wherein n1is the integer 2.

48. The immunoconjugate of claim 45 or 46, wherein n1is the integer 5.

49. A polynucleotide encoding the antibody or the antigen-binding fragment thereof of any one of claims 1, 2, and 37-44, or the antibody or the antigen-binding fragment thereof of the immunoconjugate of any one of claims 3-48.

50. An expression vector comprising the polynucleotide of claim 49.

51. A cell comprising the expression vector of claim 50.307MF-363630230Attorney Docket No. 22419-20012.4052. A cell capable of producing the antibody or the antigen-binding fragment thereof of any one of claims 1, 2, and 38-44 or polypeptide components of the immunoconjugate of any one of claims 3-48.

53. A pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof of any one of claims 1, 2, and 38-44 or the immunoconjugate of any one of claims 3-48, and a pharmaceutically acceptable excipient, salt, carrier, or diluent.

54. The pharmaceutical composition of claim 53 for use in modulating the immune system by inhibiting binding to DDR1.

55. The pharmaceutical composition of claim 53 for use in treating cancer characterized by expression of DDR1 in a subject.

56. A method of treating cancer characterized by expression of DDR1 comprising administering a therapeutically effective amount of the antibody or the antigen-binding fragment thereof of any one of claims 1, 2, and 38-44 or the immunoconjugate of any one of claims 3-48 to a subject in need thereof.

57. The method of claim 56, further comprising administering an additional anti-cancer therapy selected from surgery, chemotherapy, radiotherapy, and immunotherapy.

58. The method of claim 56 or 57, further comprising administering to the subject an immune-modulator, activated lymphocyte cell, kinase inhibitor, or a chemotherapeutic agent.

59. The method of any one of claims 56-58, wherein the cancer is a solid tumor.

60. The method of any one of claims 56-59, wherein the cancer is colon cancer, pancreatic cancer, prostate cancer, breast cancer, head and neck squamous cell carcinoma, head and neck cancer, renal cancer, melanoma, colorectal cancer, diffuse large B cell lymphoma (DLBCL), uterine cancer, lung cancer, squamous non-small cell lung cancer, non-small cell lung cancer adenocarcinoma, ovarian cancer, skin cancer, bladder cancer, urothelial cancer, thyroid cancer, cervical cancer, kidney cancer, brain cancer, central nervous system (CNS) or 308MF-363630230Attorney Docket No. 22419-20012.40peripheral nervous system (PNS) cancer, stomach cancer, gastric cancer, esophageal cancer, testicular cancer, liver cancer, hepatocellular cancer, lymphoma, sarcoma, and soft tissue cancer.

61. The method of claim 60, wherein the breast cancer is triple negative breast cancer.

62. A method of diagnosing or prognosing cancer in a subject, the method comprising determining expression level of DDR1 in a biological samples using the antibody or the antigen-binding fragment thereof of any one of claims 1, 2, and 38-44 or the immunoconjugate of any one of claims 3-48.

63. Use of an effective amount of the antibody or the antigen-binding fragment thereof of any one of claims 1, 2, and 38-44 or the immunoconjugate of any one of claims 3-48 for treating cancer in a subject in need thereof.

64. The use of claim 63, wherein the cancer is a solid tumor.

65. The use of claim 63 or 64, wherein the cancer is colon cancer, pancreatic cancer, prostate cancer, breast cancer, head and neck squamous cell carcinoma, head and neck cancer, renal cancer, melanoma, colorectal cancer, DLBCL, uterine cancer, lung cancer, squamous nonsmall cell lung cancer, non-small cell lung cancer adenocarcinoma, ovarian cancer, skin cancer, bladder cancer, urothelial cancer, thyroid cancer, cervical cancer, kidney cancer, brain cancer, CNS or PNS cancer, stomach cancer, gastric cancer, esophageal cancer, testicular cancer, liver cancer, hepatocellular cancer, lymphoma, sarcoma, and soft tissue cancer.

66. The use of claim 65, wherein the breast cancer is triple negative breast cancer.

67. A kit comprising the antibody or the antigen-binding fragment thereof of any one of claims 1, 2, and 38-44 or the immunoconjugate of any one of claims 3-48 and instructions for use.

68. A composition comprising a plurality of the immunoconjugates of any one of claims 17-48, wherein the average n of the plurality of the immunoconjugates is a number from 1 to 10.309MF-363630230

Images